

OBN supporting and bringing together the UK's life sciences companies, corporate partners and investors

CONNECT

Funding Future Innovations

UKI2S Give Expert Advice

Brexit & The Life Sciences Industry:

WHAT DOES BREXIT
MEAN FOR YOU?

SPOTLIGHT: Tackling The Super Bug Crisis

Dr Peter Jackson, Executive Director at the AMR Centre provides an insight into what action is being taken to deal with this global crisis

BioTrinity 2020

Inspiring Growth and Creating Opportunities in Life Sciences



DIGITALLY DELIVERED
28 APRIL - 01 MAY 2020

Organised by



www.BioTrinity.com
@BioTrinity
#BioTrinity2020

CONTENTS

OBN Network News	04
Latest developments in the Life Sciences industry	06
NEW Vaccines Manufacturing and Innovation Centre Coming to Oxfordshire	12
SPOTLIGHT: Tackling the Superbug Crisis	16
Brexit & The Life Sciences Industry....	20
Leaving the EU	21
Brexit: The Road Ahead	24
What Brexit will mean for the movement of goods?	26
Going to America?	28
Funding Future Innovations	32
THE BIOTECH BULLDOG COVID-19: The light at the end of the tunnel	36
OBN Members Directory	38



Contact details:

Main Office
OBN (UK) Ltd
5F Park Square, Milton Park, Abingdon,
Oxfordshire, OX14 4RR, UK

Tel: +44 (0) 1235 420 870

Events Enquiry:
events@obn.org.uk

Membership Enquiry:
membership@obn.org.uk

General Enquiry:
info@obn.org.uk



Welcome to CONNECT

My name is John Harris, the CEO of OBN and I'd like to personally welcome each of you to this second edition of CONNECT, our new, bi-annual magazine.

The thought process behind **CONNECT** is to reach out to our many Members and friends across the globe highlighting important sector news and offering thought-provoking opinion pieces. The level of positive response we received following our inaugural edition in Autumn 2019 was quite incredible and demonstrated that there was both a clear demand and a strong enthusiasm to see us continue to grow **CONNECT** for the future.

Suitably energised, we've pulled together what we hope you will agree is an informative, interesting, varied, and stimulating read.

As always, we very much welcome feedback and indeed suggested items for inclusion, so do let us know your thoughts as **CONNECT** inevitably evolves and develops over the coming editions.

And once you've finished with your copy of **CONNECT**, do please pass it around your organisation. OBN's 420+ Members are all companies rather than individuals – this means that every staff member whatever their role can benefit from the membership proposition and leverage OBN's wide range of services and activities.

WELCOME TO CONNECT!

Follow us on:  @OBN_UK  OBN (UK) Ltd

Visit us online: www.obn.org.uk

CONNECT is OBN's Membership Magazine produced twice a year. It is designed and printed by Incorporate Design. The main purpose of CONNECT is to provide updates on current sector issues and a listing of OBN Members and supporters. Our readers are from companies and organisations who operate within the life sciences industry in sectors such as Therapeutic Discovery and Development, Medtech, CXO/Consultancy, Academia, R&D Support and Supply, Investment, Charity and Government. The Members Directory was up-to-date at the time when this magazine was collated and will always be subject to change. Any opinions expressed by those quoted in this magazine are their own and do not necessarily represent or reflect those of OBN (UK) Ltd. No part of this publication may be reproduced or used in any form of advertising or promotion without permission of OBN (UK) Ltd.

OBN NETWORK NEWS

There has been so much positive activity in the life sciences industry since the last edition of CONNECT, despite the impact of COVID-19. Below are handfuls of the latest innovation, investment, drug and clinical developments.



Spun out of Oxford University in 2017 has received 510(K) clearance from the U.S. FDA for its image analysis system, EchoGo that applies artificial intelligence (AI) to automate the analysis and quantification of ultrasound-based heart scans. This is a major milestone and makes EchoGo available to clinicians and healthcare providers in the US.



Isansys, continues to make progress with the adoption of its Patient Status Engine (PSE) continuous patient monitoring platform. Most recently this wireless monitoring technology has been hospital-wide in a Queensland rural hospital, revolutionising its approach to the most basic process in healthcare – taking and recording patients' vital signs.



Renovos received the first investment from Orthopaedic Research UK (ORUK) and the HS accelerator's new medical research charity, the Ronald Furlong Fund. The £140k investment will be used to develop a new nanoclay gel technology, Renovite, which has the potential to transform orthopaedic surgery by allowing regenerative therapeutic agents to be precisely delivered and localised to the sites where needed.



Grey Wolf continued its successful fundraising activity with a £2.5m A2 round which will accelerate development of therapies targeting endoplasmic reticulum aminopeptidases (ERAP's), key components of the antigen presentation pathway. ERAP approaches aim to make cancer cells more visible to the immune system and hold promise for improving the effectiveness of immunotherapies.



CytoSeek, the University of Bristol spin-out, secured £1.1m to develop its pioneering cell membrane augmentation technology to effectively 'paint' the surface of immune cells and 'supercharge' their performance against solid tumours. The protein 'paint' alters the functionality of the cells including tissue specific targeting and enhanced cell survivability both key to realising the therapeutic effect of current cell-based therapies.



Emergex Vaccines has recently completed a Series A fundraising of US\$11m. This will support the clinical development of their 'set-point' vaccines, a pipeline of purely synthetic vaccines (with no biological components). First to be tested will be a Dengue vaccines followed a Universal Flu vaccine and filovirus programmes



OMass Therapeutics continued its successful fundraising by attracting a further £27.5m to add to its earlier Series A. With £41.5m raised since 2018 it can now forge ahead with development of its 'native' mass spectrometry platform and progression of its pipeline of small molecules targeting immunological and genetic disorders




Sitryx added to its very successful Series A fundraising of \$30m from October 2018 with an additional £8m equity fundraising. This will accelerate development of its pipeline focused on regulating cell metabolism to develop disease modifying therapeutics in immuno-oncology and immuno-inflammation.

In March 2020 Eli Lilly and Company announced an exclusive global licensing and research collaboration with Sitryx that could lead to potential new medicines for autoimmune diseases.



Arctoris opened its new facility on Milton Park and completed a £3.2m funding round. Arctoris provides fully automated drug discovery platform for virtual and traditional biotechnology companies, pharmaceutical corporations and academia and aims to accelerate the drug discovery process by increasing the accuracy and reproducibility of experiments.



Exonate announced a collaboration with Janssen to develop a new eye drop for the treatment of retinal vascular diseases including wet age-related macular degeneration (AMD) and diabetic macular oedema (DMO). Exonate's expertise lies in developing mRNA-targeting treatment for ophthalmic diseases.



EndoMag which has developed a minimally invasive way for physicians to locate breast cancer tumours was recognised for its strong sales performance in Europe and the US in the Sunday Times Hiscox Tech Track 100 league table



Pathios Therapeutics, established to capitalise on emerging scientific evidence that the pH sensing GPCR, GPR65, is a critical regulator of T-cells and tumour associated macrophages, completed an \$8.8m Series A. This will be applied to development of therapies for autoimmune disease and cancer.

LATEST DEVELOPMENTS IN THE LIFE SCIENCES INDUSTRY



ReCONNECT: Horton International, Diamond Pharma Services, and Pennington Manches Cooper provide their latest updates

THE GLOBAL TALENT VISA – A STEP IN THE RIGHT DIRECTION?

As the UK has now left the European Union (notwithstanding the transition period), I took time to look back at an article I wrote in November 2015, before the EU referendum had even taken place. I spoke about the importance of the Life Sciences sector to the UK, the investment in biomedical research and the establishment of world class institutes such as the Francis Crick Institute, the various Catapults and International Innovation Centres around the country. I concluded, “For this all to work and continue to grow, we also have to be able to attract the very best scientists.”

According to a recent article by Pallab Ghosh, the BBC’s Science Correspondent, EU researchers account for about half of the total UK scientific workforce of 211,000. Currently, they do not need visas to work in the UK but freedom of movement between the UK and EU is expected to end after the Brexit transition period on 31 December 2020. This has caused great concern in many quarters regarding the type of visa system that may have been introduced.

There has been a sense of relief when the Government announced a fast-track visa system (due to commence on 20th February), designed to attract the world’s leading scientists. The Global Talent Visa will have

no cap on the numbers of suitably qualified people able to come to the UK. What has pleased many research organisations and industry bodies, who have long been lobbying the government, is that the system will be managed by UKRI (with the support of recognised funders including the MRC and the BBSRC) rather than the Home Office.

“For this all to work and continue to grow, we also have to be able to attract the very best scientists.”

In the word of Venki Ramakrishnan, President of the Royal Society “The Government has listened to the research community, and this is an important first step in creating the visa system that we need for attracting global scientific talent – one that is welcoming, faster and more flexible, and takes into account the long-term aspirations of scientists and their families.”

Paul Edwards,
Managing Partner, Horton International UK



REGULATORY UPDATE

Covid-19

The European Medicines Agency (EMA) have published recommendations for sponsors on how to manage the conduct of clinical trials in the context of the Covid-19 pandemic. It provides information on changes which may be needed in the conduct of trials to deal with situations such as if trial participants need to be in self-isolation, access to public places (including hospitals) is limited due to national lockdowns, and the reallocation of healthcare professionals. It includes a harmonised set of recommendations to ensure the safety of trial participants across the EU while preserving the quality of the data generated.



Medical devices

In 2017 The EMA introduced the new medical devices regulation (MDR) EU-2017/745, and the new in vitro diagnostic medical devices regulation (IVDR) EU-2017/746, replacing three existing Directives (93/42/EEC, 98/79/EC and 90/385/EEC) for medical devices. The MDR was due to come into force on the 26th May 2020, however while not officially announced at the time of going to press it is expected that the EMA will delay its implementation for a period so that medical device companies can focus on the supplying healthcare providers with equipment and diagnostics needed during the Covid-19 pandemic.

Clinical trials

The MHRA and Health Research Authority (HRA) have been running a pilot scheme for the approval and ongoing management of clinical trials known as the Combined Ways of Working (CWoW) scheme. The CWoW streamlines the process by combining both the MHRA clinical trials authorisation (CTA) application and Research Ethics Committee (REC) application into a single submission. This allows for a reduction in the submission of duplicated documents, a single communication channel with the MHRA and REC, joint receipt of questions and approvals leading to a faster overall process.

Diamond have been assisting clients to navigate through the pilot scheme. One aim of the CWoW was to have a joint decision from the MHRA and REC by day 60. After the first year of the pilot the average approval time is as little as 42 days. Diamond's experience has been in keeping with this, highlighting the effectiveness of the new scheme. We understand that CWoW will shortly be open to all applicants, however this has not been formally confirmed by the MHRA or HRA.

Further guidance can be accessed via the EMA website [here](#).

For further information please contact: Roley Davis, Senior Business Development Manager, Regulatory, RDavis@diamondpharmaservices.com

IS YOUR BUSINESS READY FOR THE UPCOMING CHANGES TO THE IR35 "OFF-PAYROLL" WORKING TAX RULES?

Kathy Hills, Partner, Pennington Manches Cooper and a Member of the OBN Investment & Tax Special Interest Group (ITSIG) provides expert advice on what this will mean for private sector companies.

The changes come into force for those operating in the private sector for any payments made to relevant contractors on or after 6 April 2021. Because the rules apply by reference to the payment date, they may apply to work undertaken prior to 6 April.

Does this apply to you?

The IR35 / "off-payroll working" rules apply to those who provide services to engagers via a personal service company (PSC). They apply where, if the relationship had been a direct engagement between the individual contractor and the engager, it would have been one of employment for tax purposes. The rules operate to charge tax and National Insurance contributions (NICs) at broadly the same rate as that charged for employees. Historically, the IR35 tax charge has provided for a 5% deduction which recognises the costs of

running a company. However, there is no such deduction under the new rules.

Currently, the responsibility for any tax arising under IR35 for a private sector contract will sit with the PSC, apart from in limited circumstances involving fraudulent behaviour by an engager.

Why is 6 April 2021 so important?

With effect from 6 April 2021 the private sector rules will be aligned with the public sector. It will be the engager who will be responsible for assessing whether a contractual arrangement falls within or outside IR35; and, where the arrangement falls within IR35, operating PAYE on the fees before paying the net amount to the PSC. Where an agency is involved in the supply chain, the agency will be required to operate PAYE if they are the fee payer.



What type of companies will be affected?

At the outset, the rules will only apply to medium and large companies in the private sector, so small businesses will not be required to operate the new rules at this stage.

A company will be “small” where at least two of the following are satisfied:

- it has a turnover of not more than £10.2 million;
- it has a balance sheet total of not more than £5.1 million; and/or
- it has no more than 50 employees.

In some instances, companies will need to take into account the turnover, balance sheet total and employee count of its corporate shareholders when determining if it is ‘small’ for these purposes.

“All medium and large companies engaging a worker through a PSC will be required to undertake a status determination where the payment for that service will be made on or after April 2021”



A corporate investor will be included in this test if:

- it holds the majority of the voting rights in the company (i.e. more than 50%); or
- it has the right to appoint or remove the majority of the directors; or
- it has a dominant influence over the Company (however that right is given)

What action do companies affected need to take?

All medium and large companies engaging the services of a worker through a PSC will be required to undertake a status determination for every contractual arrangement where the payment for that service will be made on or after 6 April 2021. They must then notify this determination to the PSC by way of a status determination statement (SDS). The SDS must be prepared before the first pay date after the new rules come into force in order to ensure the correct tax treatment is applied, or for new engagements after 6 April 2021, before the start of the engagement. Where an agency is responsible for paying the PSC, the SDS must also be supplied to the agency.

The SDS is a vitally important document for an engager. If an incorrect determination is made, the tax liability resulting from the incorrect IR35 status will be assessed on the engager unless they can demonstrate that they have used “reasonable care” in preparing the SDS.


Once an SDS is served on the PSC, they must be given an opportunity to appeal the determination. The engager company is required to respond to any appeal request within 45 days and a failure to do so could again lead to the engager being assessed to any tax arising from an incorrect determination, even where the SDS has been prepared with ‘reasonable care’.

HMRC has a tool (the ‘check employment status test’ (CEST)) which can be used to help determine the status of a particular engagement. However, the CEST test has been subject to a number of criticisms, particularly as the test fails properly to address mutuality of obligation, which is seen by the Tax Tribunal as one of the three key indicators of employment status. An SDS is a determination in respect of tax only; this does not conclude a contractor’s or PSC’s status for employment law purposes.



PENNINGTONS
MANCHES
COOPER

UNLOCKING POTENTIAL



Our award winning life sciences lawyers combine creativity with sharp commercial perspective.

To find out how we can help you achieve exceptional results for your business, call us on **01865 722106**, e-mail info@penningtonslaw.com or visit us online.

**LONDON BASINGSTOKE BIRMINGHAM CAMBRIDGE GUILDFORD OXFORD READING
MADRID PARIS PIRAEUS SAN FRANCISCO SÃO PAULO SINGAPORE**

www.penningtonslaw.com

Penningtons Manches Cooper
Incorporating Thomas Cooper

NEW VACCINES MANUFACTURING AND INNOVATION CENTRE COMING TO OXFORDSHIRE



“We see the Vaccines Manufacturing and Innovation Centre as a custodian of knowledge and technical expertise that can be used to accelerate the development of vaccines and in particular to support the UK’s first-class activity in the vaccine space” Matthew Duchars, CEO, VMIC.

The Vaccines Manufacturing and Innovation Centre (VMIC) is a new, not for profit, organisation providing the UK’s first strategic vaccine development and manufacturing capability. Based at Harwell Science and Innovation Campus, Oxfordshire, the Centre will form part of the UK national scientific infrastructure, providing facilities and subject matter expertise for rapid, effective and economic development and manufacture of vaccines, with the purpose of stimulating and accelerating early stage clinical development (pre-clinical through to Phase 2) as well as larger scale emergency response capability.

The highly specialist Centre will have the capability to develop, manufacture and fill multiple vaccine products including viral vectors, attenuated viruses, VLPs, glycoconjugates, nucleic acids, bacterial and subunit vaccines.

The 140,000 sq ft VMIC facility will be opening its doors in 2022 and will fast track development and manufacture of early stage vaccine products (both prophylactic and therapeutic) for product developers from around the world. It will provide both state-of-the-art facilities and expert knowledge to guide and accelerate the translation of science from discovery to clinical development, using both innovative and traditional technologies. It is envisaged that much of the work will be collaborative ventures with organisations ranging from small and medium sized businesses, through to large multinationals, thereby underpinning the activity and strength of the UK in the vaccine area.

In addition, the facility will also serve as an emergency response and stockpile capability for the UK government and other NGO’s (e.g. CEPI, Wellcome, etc), to produce vaccines against specific threats, such as emerging infectious diseases (EID) and deliberate/accidental release of biological agents.

The GMP facility, housing state of the art laboratory equipment, will consist of ten process and analytical development laboratories, four manufacturing suites and fill finish capability to produce 100 -100,000 units per day (including live viral). The clean rooms will be BSL2 (suitable for production of non-replicating viral vectors and live attenuated viral vaccines), operating initially at 10 L and

50-200 L scales but having the capability to be used at 1000 L scale. It will have dedicated Quality Control laboratories, warehousing and associated utilities, as well as office space for both staff and collaborators.



VMIC at Harwell Science and Innovation Campus

Locating VMIC within the Harwell HealthTec Cluster is a natural choice given the superb infrastructure and expertise on site including several national facilities involved in pioneering Life Sciences research such as the Rosalind Franklin Institute, the Diamond Light Source, the Nucleic Acid Therapy Accelerator and the recently announced Extreme Photonics Applications Centre, as well as a growing number of Life Science companies. Having recently secured the Life Sciences Opportunity Zone status, one of only seven sites in the UK, Harwell is already a world-renowned science and technology campus.

The HealthTec cluster collectively employs


1,250 people, across 58 organizations on the 700-acre campus, which has space for the future expansion. Research spans a wide range of activities including drug discovery, AI-enhanced drug design, vaccines, vectors and advanced medicines, through to environmental impacts on human health, biomaterials and ageing. Globally unique technical capabilities include multi-modal imaging in structural biology, genomics, big data analytics and super-computing.

VMIC is a great addition to the Harwell Campus and the surrounding region, bringing in sixty new high-tech jobs at its opening and expanding to 130 as the company grows.

Who is supporting VMIC?

VMIC is supported by its three founding academic institutions (The University of Oxford, Imperial College London and The London School of Hygiene and Tropical Medicine) with support from three industrial partners (Merck, J&J and GE Healthcare). Funding for the capital build is being provided by the UK Government through Innovate UK, with additional contributions from each of the industrial partners and the Wellcome foundation. Design work is complete, and work is about to start on the build of the facility, with the Centre expecting to become operational in 2022.

.....
*For more information about the Harwell HealthTec Cluster please contact
Adrian Hill, HealthTec Cluster Manager:
adrian.hill@stfc.ac.uk*
.....



**HealthTec
at Harwell**
MULTIDISCIPLINARY
INNOVATION

Harwell Campus, a world-leading innovation hub and 'Life Sciences Opportunity Zone'

The Vaccines Manufacturing and Innovation Centre (VMIC) will soon join the Rosalind Franklin Institute and Nucleic Acid Therapy Accelerator as part of £280m of recent developments at Harwell Campus.


Harwell brings together a thriving, collaborative ecosystem of industry, academia and public sector bodies with >£2bn of open access national laboratory facilities.

Core Capabilities

- Drug discovery, design and delivery
- Vaccines, vector technologies and advanced medicines
- Medical imaging, devices, bioinformatics, advanced materials and diagnostics
- Environmental impact on human health

Globally unique imaging capabilities and solution-based services

- Next generation sub-cellular imaging, chemistry and drug design
- Structural biology, crystallography, Cryo-Electron Microscopy (EM), Ultra High Resolution TEM and STEM Imaging, X-ray Tomography
- Super resolution fluorescence imaging, Live cell non-invasive imaging
- Fragment screening and protein production
- Liquid, polymer and protein surface analytics
- Dosimetry & Analytical Ultra Centrifuge
- International Mouse Genome repository
- Digital communications and satellite applications for telemedicine, space medicine, and health and environmental monitoring



www.harwellcampus.com @HarwellCampus Tel: +44 (0) 1235 250 091



VMIC welcome early communications on potential collaborative opportunities from perspective organisations. To find out more contact our team via info@vmicuk.com

TACKLING THE SUPERBUG CRISIS

SPOTLIGHT

Dr Peter Jackson, Executive Director at the AMR Centre provides an insight into what action is being taken to deal with this global crisis

With public health leaders long warning of the increase in the number of multi-drug-resistant pathogens, the need for new and innovative forms of antimicrobial drugs could not be greater. Indeed, the phrase “post-antibiotic era” can no longer be used in the future-tense. With everyday infections becoming resistant to ever increasing classes of extant antibiotics, these once miracle drugs are no longer performing miracles.

Clearly, there is an urgent need for a strong pipeline of new antimicrobial drugs, but the recent World Health Organisation (WHO) report on antibacterial agents in clinical development showed that progress is inadequate, and there remain several great challenges to be overcome that are standing in the way of effective antimicrobial R&D.

One such challenge is the lack of a clear route to market for new drugs. Investors agree with the need for new drugs but raise questions as to how to make an acceptable return on investment, given the risks involved. Recent company failures have quelled enthusiasm amongst investors, resulting in an extremely difficult funding environment.

One such case is American firm Achaogen, which spent hundreds of millions of dollars and 15 years developing Zemdri, an effective drug to treat urinary tract infections. However, in April, Achaogen declared bankruptcy, after failing to make a significant impact in the market. In January 2020, the situation has got worse, with another antibiotics firm, Melinta Therapeutics, also filing for bankruptcy.

There is another more fundamental challenge in store for antibiotic development firms. Innovators must be rewarded for their work in developing new treatments for life-threatening infections, but this must be carefully balanced against the public health need to use drugs sparingly to avoid unnecessary development of

Investors agree with the need for new drugs



further resistance to these new drugs as well. We need to 'de-link' the reward for innovation from the commercial pressure to prescribe more drugs.

Governments and other payers are only now starting to think about how to value and reimburse new treatments to incentivise developers and take us towards a new marketplace for AMR drugs. Thankfully, there are some positive steps being taken to address the problems with antimicrobial drug development.

This welcome move by the UK will make it more attractive for companies to invest in AMR R&D, and their shareholders to support them

In the UK, NHS England is collaborating with National Institute for Health and Care Excellence (NICE) on a pilot project under which NHS England will evaluate and procure two AMR drugs on a trial basis – de-linking the valuation and reward payments from the medicines' usage. It will test a 'subscription' style model that pays pharmaceutical



companies upfront for access to drugs based on their usefulness and value to the NHS and wider society.

This welcome move by the UK will make it more attractive for companies to invest in AMR R&D, and their shareholders to support them, sending a strong signal that the UK Government is serious about fixing the broken market for the long term.

While we wait with anticipation of rapid progress on investment and reimbursement, I believe there is still plenty of scope for further innovation in the AMR market, in particular to encourage a vibrant drug development network.

The UK's AMR Centre (AMRC) is an important element within this emerging AMR ecosystem, providing an alternative pathway for drug developers to progress their projects into clinical trials, by offering in-kind pre-clinical and clinical development capacity in return for a share of future commercial revenues.


July 2019 saw AMRC take forward an anti-virulence program developed by the Japanese pharma company Shionogi. The project, COT-143, is a novel therapy designed to help the body tackle *Pseudomonas aeruginosa* (Pa) infections, a hard-to-treat and often drug-resistant pathogen recognised by the WHO as a critical priority threat to human health.

AMRC also ended 2019 by achieving a key milestone, the nomination of a preclinical development candidate in our MET-X program, tackling drug resistance conferred by NDM-1 and other metallo- β -lactamase (MBL) enzymes. The MET-X program was in-licensed from Swedish company Medivir and is focused on a novel small molecule that, when used in combination with β -lactam antibiotics, restores their function.

The AMRC's scientists have now got 12 months of work to do to confirm that the new drug is safe for use in humans, and to manufacture trial quantities of drug to support the first clinical trials, planned for late 2020.


Despite uncertainties about the AMR sector, it is essential that we continue to push innovative drugs through the pipeline. Our patients can't afford to wait.

Dr Peter Jackson
Executive Director, AMR Centre



AMR CENTRE

The UK R&D Centre for Antimicrobial Resistance



Working to develop new and novel antimicrobial therapeutics, to tackle the global threat from antimicrobial resistance.

AMRCentre.com Info@AMRCentre @TheAMRCentre

BREXIT & THE LIFE SCIENCES INDUSTRY

What will Brexit Mean For You?



OBN Supporters, BDO, Venner Shipley and World Courier give you expert insight into three fundamental areas of the life sciences industry; economic, IP and logistics

Leaving the EU

BDO sheds light on what this will mean for the life sciences industry...

The UK's exit from the European Union seems to be assured now that the withdrawal agreement has been passed into law and many businesses are asking themselves whether they now have sufficient certainty on the regulatory and tax landscape to move on and concentrate on business. This happy feeling has been enhanced by the fact that there is an 9-month transition period during which there will be no change to the status quo.

We would suggest however, that it may be too early to relax given that negotiations on the future trading relationship have yet to start in earnest. Whatever is agreed, it seems certain that there will be significant changes to the way goods move between the UK and the EU, which is the focus of this article. The government have been clear that the UK will not be a part of the single market and therefore goods moving across border will be imports and exports, with declarations being required and potentially customs duty as well. This latter point is important because although many medical products have a zero-duty rate, certain ingredients and associated packaging may not.

In its February opening address regarding the future relationship with the EU, the government is seeking a free trade agreement with the following ambition: "There should be no tariffs, fees, charges or quantitative restrictions between the UK and the EU. There should be a protocol setting out appropriate and modern rules of origin, in order to facilitate trade between the parties to the greatest extent possible."

Boris Johnson's opening gambit regarding goods movement did not assist businesses with reducing uncertainty: "Facilitative customs arrangements, covering all trade in goods, should be put in place in order to smooth trade between the UK and the EU. These should ensure that both customs authorities are able to protect their regulatory, security and financial interests."

The potential changes to the way goods are moved after 31 December 2020 are likely to be significant for the life science sector, where supply chains are often complicated by the regulatory framework and the need to ensure that product can be legally sold in one jurisdiction (say the EU), but manufactured and packaged elsewhere, like the UK. It is of course important that businesses know how their product will be moved and what tax or duty treatment applies once the UK is outside the EU. Some businesses will have the benefit of the expertise of third-party logistics suppliers, involved partially or wholly in that supply chain. It should be remembered of course that where declarations are made by agents on behalf of businesses, they remain the businesses' responsibility.

Of course, many businesses will have already made detailed plans which will need to be reassessed as negotiations continue. One recent development worth noting is with respect to the various easements announced



by the government last year, such as the transitional simplified procedures (TSP) and deferred accounting, which were designed to facilitate trade in the case of a hard Brexit. In a recent press release, the cabinet office confirmed that these will not now be introduced.

Whilst the statement is short on detail, it could be assumed that none of the easements will survive and that businesses will be subject to the full rigour of customs declarations and the potentially significant cash flow disadvantage

of paying VAT on imports and recovering that tax some months later in the VAT return. The temporary unilateral tariff will also be set aside and replaced with whatever comes out of the trade agreement.

Given that the worst-case scenario planning businesses have carried out so far reflects the implementation of the easements, we would suggest that businesses proactively revisit these plans and use the time during the transition period to consider the relevant Customs relief currently available.

Customs reliefs that may be helpful include:

- Authorised Economic Operator (AEO), which has a wide range of cash and facilitation benefits;
- Customs Warehousing which enables goods to be stored VAT and duty free; and
- Inward/outward processing relief which seeks to remove double duty charges when goods are moved from one place to another.

Your indirect tax and duty advisor will be able to help you to understand and apply for reliefs; and to respond to the UK's new trading relationship with the EU once finalised.

The changes to the way goods are moved will be significant to the life sciences sector



Glyn Woodhouse, partner at BDO, leads the firm's Brexit planning group for indirect tax and customs duty. Email: glyn.woodhouse@bdo.co.uk Phone: 0118 925 4446



IDEAS | PEOPLE | TRUST

CHEMICAL ENGINEER

HIKER

SONGWRITER

TECHNOLOGY WIZARD

MORE THAN AN ACCOUNTING MACHINE

Our people are wonderfully complex. We have dedicated Life Science specialists who have the knowledge and insights to provide solid foundations for your business' future growth.

bdo.co.uk

EXPERIENCED CARDIOTHORACIC SURGEON

HEALTHCARE & LIFE SCIENCES PARTNER

GAELIC FOOTBALLER

ACTOR



Brexit: The Road Ahead

James Tumbridge, Partner, Barrister at Venner Shipley

The intent of the UK Government is far clearer than the previous one, and it is highly unlikely that the end of the year date will change. So, from January 1st, 2021 the UK will be wholly separate from the EU and on its divergence course. Early signs of that has been the confirmation, that I have long expected that the Pan-European Unitary Patent Court, if it goes ahead at all, will not include the UK.

The UK Government also changed its structure of negotiation, closing the Department for Exiting the EU and instead the Prime Minister will personally oversee the negotiation task force with the EU. In this short piece I shall try to highlight some key points to watch out for in the coming months if you are in the Biotech Space.

1 Contractual jurisdiction, and enforcement of judgments

27% of the world's legal jurisdictions used English Common law (according to Sweet & Maxwell), and UK Government statistics have shown as many as 81% of parties in the London commercial courts are foreign, with over 60% of global cross border agreements choosing English law. English law is the preferred governing law for business transactions worldwide, even those that don't have any geographic connection with the UK, and the reasons behind that are nothing to do with the EU and won't change, but your jurisdiction clauses in contracts with European entities might need to be reviewed.

2 Regulatory approvals

The main Brexit change was the moving of the European Medicine Agency (EMA) from London to Amsterdam. There will be changes to the approval process in 2021, and the UK has decisions to make about how it operates in future, and how close it remains to Europe, and whether it looks to have more alignment with for example the USA.

3 Trademark changes with the loss of the EU mark for the UK

The big Brexit shift is the return to national UK trademarks and designs as the only recognised rights, and the end of EU Trademarks (EUTMs) and designs applying to the UK. You will need to have a new strategy in future, and if the UK matters to your investment, you will need separate UK rights.

4 Visa policy

This is good news for non-Europeans, the UK will have a globally level playing field, and non-Europeans will no longer be discriminated against. The UK has already announced a new Global Talent route for visas and for the first time UK Research and Innovation will endorse applicants from the scientific and research community.

5 Other Intellectual Property Issues

The big news is that the UK has finally confirmed it will not be part of the Pan-European Patent Court. There are also changes to our plans on copyright, and the future of Supplementary Protection Certificates will be considered...**so there is much to keep an eye on.**

To read James's full article then please click [here](#).

Protecting your IP. Powering your success.

We believe our role is not just to know the law but also to be commercial thinkers, working closely with life science companies to maximise their IP in a competitive environment.

Our Life Sciences team has substantial technical expertise in the fields of biotechnology, pharmaceuticals and chemistry. Uniquely we also have lawyers that work with regulators and the UK government, so we are able to guide you on how to engage with regulatory reviews and changes including the UK's relationship with Europe.

We understand the market place, the regulatory requirements, and the commercial importance that a well-managed IP portfolio has in the litigious life sciences industry. Boasting specialist patent attorneys and litigators, we are able to advise you on the whole life of your patenting needs.

We appreciate how important it is not only to fully understand our clients' technology, but also their business. This means gaining a thorough understanding of their commercial activities and aspirations and working with them to achieve their strategic goals.

Your OBN contacts.



James Tumbridge
Partner, Barrister



Anton Hutter
Partner, Patent Attorney

www.vennershipley.co.uk
info@vennershipley.co.uk



World Courier explain...

What will Brexit mean for the movement of goods?

The agreements made in 2020 have the potential to impact several markets including the pharmaceutical and life sciences industries – affecting businesses, patients, researchers, and universities for the long-term.

Already, institutions such as the European Banking Authority and the European Medicines Agency have respectively relocated to Paris and Amsterdam. Numerous major financial services have moved their central base outside the UK. And a few pharmaceutical manufacturers have moved their European HQs. Despite all the recent developments, the UK will remain in the EU's customs union and single market until January 1st, 2021.

With no customs charges or duties to shipments between the UK and EU throughout 2020, pharmaceutical companies reliant on specialty logistics services will incur no immediate financial impact due to Brexit.

Nonetheless, the UK government has confirmed plans to introduce import controls on EU goods at the border after the transition period ends. Traders in the EU and UK will have to submit customs declarations and be liable to extra goods' checks. Due to the complex nature of the funding, research, and compliance structures inherent in the pharmaceutical and life sciences industries – these changes could massively disrupt growth.

The UK's withdrawal from the EU after the transition period on December 31st, 2020 will have a large impact on the regulation of medicines, medical devices, and clinical trials. Businesses can expect more stringent import controls, additional duty payments for certain goods, and increased lead times.

Businesses in the pharmaceutical and life sciences industries can stay ahead and help mitigate the impact of border controls and Brexit by:

- Making sure they have an Economic Operator Registration and Identification (EORI) number
- Creating declarations using a customs agent
- Shipping specialty logistic products using an Authorized Economic Operator (AEOC)

World Courier's role in the international supply chain as a specialty logistics provider is recognized globally. Being the only major logistics provider in the UK with Authorized Economic Operator (AEOC) Customs Simplification status facilitates trust between pharmaceutical and life science companies looking to import or export products across the UK border.

With Horizon 2020 funding being reduced, and the unexpected dynamic nature of Brexit, working with a logistics company who is trained on all new requirements relating to the EU-UK movements of goods, can help pave the way to a seamless transition post-Brexit.

World Courier is the only logistics company with global GDP certification against three major GDP standards, (EU GDP, USP 1079 and WHO GDP). And as the updates concerning Brexit continue to develop, the company will adjust its risk mitigation approach in line with the best interests of customers and patients.

For further information please contact Alan Runacus Business Development Manager, arunacus@worldcourier.co.uk



BioForward

The 'Roadmap for Growth' Life Sciences Event



SPONSOR, EXHIBIT, ATTEND

OXFORD 05 OCTOBER 2020

Organised by



www.bioforward.co.uk
[@BioForwardUK](https://twitter.com/BioForwardUK)
[#BioForward](https://twitter.com/BioForward)

GOING TO AMERICA?



How to ensure that your entry in the US market runs as smoothly as possible. VABeachBio shares their advice

Growing your healthcare business into the United States will not get far without a physical presence over there. US customers expect it and transport, time zones, even your accent on the phone can slash your technical advantages in the world's most competitive market.

So how to do it? You may be able to work through a US representative or distributor. However complex biotech technologies are not picked up overnight, so many firms choose to set up their own operations stateside.

It's a daunting prospect, and in amongst all the questions of recruitment, FDA, finance and legal issues is the knotty issue of location. The expensive Boston and San Francisco areas are well-established in the biotech world, but there are other up-and-coming places that can work better.

One of these is Virginia Beach, the largest city in the state of Virginia. We spoke to their Director of Economic Development, Taylor Adams.



INTERVIEW

Taylor Adams, Director of Economic Development, City of Virginia Beach

Why should a UK biotech company consider Virginia beach?

What we call 'the biotech sector' is of course dozens of specialist areas across devices, drugs, services and different therapeutic needs, and the supporting investor community and specialist services. Every bio company is different, and while we are perfect for some, we may not fit everybody – and I think that is true of many biotech clusters in the USA. We are strong in diabetes, regenerative medicine, cardiology, cancer, piezo-electrics, photon therapies and simulation training. Reproductive health and urology are important too – we had the first US test-tube baby here.

Who are the bigger players in the Virginia Beach biotech cluster?

The biggest are LifeNet Health, one of the US's largest organ donation and transplant operations, and Sentara Healthcare, a major hospital and health services provider. One I am especially proud of is Operation Smile, which is based here. It is a global charity that provides 15,000 cleft palate operations a year in 60 countries. Clustering happens in all sorts of niches - our specialism in liver disease research has attracted a Spanish



company here recently to partner with a local firm.

How well does the region provide the talent that companies need?

I'm glad you asked me that. We have an excellent array of schools including Eastern Virginia Medical School and Old Dominion University covering a huge range of top-end academics and research, not just the Medicine and Biomedical Science courses you would expect. For example, there are even Masters in Healthcare Data Analytics, Pathology or Athletic Training.

Convergence Center - the location for Virginia Beach's new biotech Incubator facilities and labs

It is not just the heady heights that are catered for. Our local college system also covers a variety of lab and imaging technician, nursing and therapist programs.

How does your office help incoming companies?

We have a full and free 'hand-holding' service. As well as finding your office, lab, warehousing or factory space, we connect you with all the specialist advisers you need, from recruiters, bank managers and

investors to healthcare lawyers and FDA consultants.

Later this year we are opening a new VA Beach Bio Accelerator facility which will be perfect for incoming British companies. It has 6,000 square feet of office space, virtual offices and shared wet lab.

So, I'd say to any UK biotech company looking at the US, let us show you what we can do for you!

Washington DC

Virginia Beach

- 450,000 population.
- Popular tourist resort.
- Three-hour drive from Washington DC.
- Direct flights to most major US cities.

Virginia

- More than 600 biomedical/ life science companies.
- Over 20,000 people employed in healthcare.
- \$1.9 billion in biomedical/ life science-related capital investment in the last decade.

CONTACT

UK representative: Charles Macdowell
cmacdow@vbgov.com

OBN Membership

JOIN OVER 400 MEMBER COMPANIES BENEFITING FROM OUR SERVICES

Membership to OBN gives you access to partnering, purchasing, training, advice and advocacy. Learn from your peers and grow your business.

Membership criteria

OBN Membership is open to:

- UK and international companies
- Investors
- Academic and research institutions
- Independent consultants
- Contract research organisations
- Public bodies
- Government departments
- Associated service providers in the life sciences sector

Membership Benefits Networking -

Attend OBN events

- Connect with life sciences companies, their corporate partners and investors
- Expand your company's presentation opportunities
- BioTuesdays – evening meetings with a sector-relevant theme or a Company Showcase format
- BioThirstdays – evening social events to meet informally
- Senior Executive Club – Breakfast, Lunches and Dinners: invitation events, high level focus materials

Plus many more..

Advocacy

- Promoting Members' interests at local, regional and international level
- Attend exclusive events to connect with influencers and key decision makers

Partnering

- £300 discounted registration at BioTrinity –OBN's flagship event and Europe's leading Biopartnering and Investment Conference. Engage with 1,000+ delegates from 30 countries
- Access conference discounts worth over £1,000 per person
- Request introductions to key personnel

Purchasing

- Access average savings of 50% off list price through the OBN Purchasing Consortium
- Buy alongside 110+ eligible Member companies
- Process managed by an in-house Procurement Manager
- Access to a new online Purchasing Platform

Training

- Use BioLearn® to access high level training tailored to the needs and requirements of life sciences staff at discounted prices

Advice

- Find facilities, equipment, expertise within the OBN Membership and in other geographical areas
- Make contacts through our partner organisations
- Canvass opinion and consult on key issues for your company
- Commission OBN Intelligence to address key issues for your organisation



To find out more about OBN Membership benefits visit: obn.org.uk or contact Nicola Westgate, Membership Manager, nicola.westgate@obn.org.uk or call +44 (0)1235 420879

FUNDING FUTURE INNOVATIONS



The UK Innovation & Science Seed Fund (UKI2S) gives insight into early stage investment

Early-stage investment

Seed stage funding is a crucial step for early stage life sciences companies in achieving long term success. It can provide essential support to overcome the challenges and pitfalls associated with getting a new business off the ground. However, early ventures pose risks for investors, such as incomplete management teams, technology development risk, an uncertain route to market, being too early for fully commercial sales, incomplete funding packages and lack of visibility on exit.

The UK Innovation & Science Seed Fund (UKI2S), formerly Rainbow Seed Fund, is one of the few funds that invests in ideas and early-stage technologies, kick-starting entrepreneurs' ideas to launch science-based companies that can deliver important innovations. The seed fund invests at the earliest stages of technology development, including pre-company stages, from £25k to £1m. UKI2S is a patient capital fund, meaning it can invest for as long as it takes to take technology to a great exit. It's also a high risk high growth fund and actively seeks big ideas across the universe of life sciences

What do investors want to see from early stage companies?

As deep tech investors, we look for four key things:

- 1 Technical.** We want to see technical proof of concept – this can be in the form of an experiment, a published paper or an extensive literature review.
- 2 Founders.** We want to see founders with strong technical capabilities and ambition.
- 3 Awareness.** We look for awareness of the competition – it is essential for the company to be able to state why its technology is addressing an unmet need.
- 4 A plan.** We want to see a plan; for a seed-stage company, an 18-month plan with a cash forecast means that an investor can quickly understand the value of inflection points and the type of investors the company will need.





The impact of timely investment

UKI2S has been instrumental in the creation and development of many bioscience companies. For instance, UKI2S was the founding investor in Quethera, a gene therapy company focused on glaucoma, founded in 2014. The Fund backed the team to develop its novel ocular disorder therapy despite the high level of technical risk. It helped shape the company by leading the investment rounds to exit, providing strategic advice and playing an active role on the board. Three years after the company was founded, Astellas Pharmaceuticals bought Quethera for £85m.

Another UKI2S success story is Atelerix, a company with a transformative technology for the storage and transport of viable cells at room temperature, overcoming the limitations of the current need for cryo-shipping. UKI2S helped in the spin-

out process from Newcastle University, recognising the immense technical value of Professor Che Connor's patented technology to revolutionise the transport of viable cells. UKI2S provided early-stage funding and introduced the company to other investors, enabling the rapid growth of the team. Within two years of incorporation, the company is now generating revenue and is in discussions with several of the Top 20 Big Pharma to evaluate the feasibility of collaboration for the shipping of CAR-T therapies.

Independent analysis of the UKI2S Fund showed that over 70% of its companies would not have existed without the Fund's support, and its investment has been leveraged by over £500M of third-party investment, illustrating that seed stage funding is a crucial source of support for life science venture creation and company growth.


Please get in touch to find out more: ukinnovationscienceseedfund.co.uk



UK INNOVATION & SCIENCE SEED FUND

Bridging the gap from lab to market

High-risk, high-growth early-stage venture capital fund creating world-leading companies from the UK's research base



UK Research and Innovation

Backed by UK Research and Innovation (UKRI) and partnered with nine publicly funded research bodies

If you are an entrepreneur starting a synthetic biology company we want to hear from you. Contact enquiries@UKI2S.co.uk

ukinnovationscienceseedfund.co.uk

THE BIOTECH BULLDOG



COVID-19: The light at the end of the tunnel

As I write, at the beginning of March, the reported toll taken by COVID-19 includes 3,000 lives. In addition, although less importantly, approximately \$5Tn has been wiped off of the global markets as companies, traders and investors struggle to understand the full implications of the infection, and subsequent actions to control the virus, on global trade and industry. It is likely that by the time this article is published the landscape will have changed, as we rapidly accumulate additional data regarding the virus and its transmission, although this will sadly be accompanied by sometimes panic stricken media coverage that publicises the most alarmist scenarios. However, as with all disease the virus will be constrained by its inherent capabilities and be impeded by sensible healthcare responses, and longer-term innovations. As such, based on current available data, we are optimistic, although acknowledge that in order to minimise morbidity and mortality governments around the world will have to act rapidly and effectively.

As for all diseases perhaps the most important quantitative components are R^0 (basic reproduction rate – the number of secondary infections resulting from a single infection) and the case fatality rate (CFR; the proportion of those infected are likely to die). As with all 'new' infections a reliable estimate of these two factors is not easily derived. However, the most reliable data to date (WHO/ Chinese CDC/ Journal of the American Medical Association based on a study of 72,000 patients) suggest that the causative agent of COVID -19 (SARS-CoV-2) has a range of potential R^0 values, and a CFR of 2.3%. It has been noted that in the case of Diamond Princess cruise ship patients, an R^0 of 2.28 was observed, although whether this is a useful metric given the peculiarity of the population from which it was derived is unclear. The WHO cites an observed R^0 of 2.0 to 2.5, although it has been speculated that it could be higher. The CFR is of course, an average, with much higher mortality rates amongst the elderly (8% in those aged 70 to 79 and 14.8% in those over 80%) and infirm. It's noteworthy, and perhaps poorly publicised, that in an analysis of Chinese data just 1% of cases occur in children (younger than 9; 11.9% of the Chinese population) and young adults (10-19; 11.6% of the Chinese population). We note that these numbers are based primarily on the pattern of disease in China, and as such may reflect factors specific to that population. To put this in perspective influenza the R_0 rate for influenza in China of 1.3-2.5 have been observed in community settings, whilst higher rates have been observed in international studies of closed environments (boarding schools, military facilities and nursing homes), with up to 40-60% infection rates, even reaching 71% (albeit in a 1979 boarding school study). Whilst the disease is still

Historical comparisons should be treated with great caution

in its early stages, and factors such as number of asymptomatic carriers and latent period clearly impact R^0 , it is likely that reports that up to 70% of the European population may become infected with SARS-CoV-2 may be alarmist. These levels of infection have been hypothesised before, although only in the context of diseases with significantly higher R^0 s (i.e. >10). We note that CFRs for influenza are approximately 0.1%, although for the 1918 flu outbreak it was closer to 2.5%. However, historical comparisons should be treated with great caution, as mortality in particular reflects population health, education, wealth, access to healthcare, treatment, seasonality and control measures (i.e. the 1918 environment was very different).

Similarly, the original Lancet report of a CFR of 11% of the first 99 patients admitted to hospital in Wuhan is unremarkable given that these were likely those with the most advanced symptoms. R^0 of 10 and a 30% CFR. The initial reaction to news of the disease by Western countries, including the UK was at best haphazard and at worse incompetent, even allowing for citizenries that react poorly to restrictions on personal freedom of choice (i.e. enforced quarantine of passengers). However, as perhaps expected, in terms of preparedness the US CDC has so far perhaps produced the

Look out for the Biotech Bulldog's next report in our Autumn issue of CONNECT



most comprehensive and cohesive response in terms of advice and planning (with to date 23 actionable Guidance documents), although whether a cohesive Federal approach or less coordinated state-wise response will be adopted is uncertain. The UK will undoubtedly have to finesse its response in due course, with severe movement restrictions (perhaps for many months), procurement of additional equipment (i.e. diagnostics and respirators), mobilisation of armed force support, expansion of NHS care facilities and daily mortality rates exceeding 1,000 are all highly likely (NB annual deaths from seasonal flu sometimes already exceed 15,000 and 50,000 in the UK and US respectively). Clearly as the infection progresses more data will become available, the analysis of which will facilitate a more finely tuned response by all relevant authorities. However, whilst the disease characteristics are a concern (with a significant increase in morbidity and mortality), any government-coordinated response should will undoubtedly fall short of panic or, even given likely media hyperbole and the spectre of 'fake news', the latter often instigated by overseas governments (sometimes attempting to 'save face').

Fortunately, in the West at least, the full weight of relevant healthcare systems will be brought to bear against COVID-19. Longer-term the most appropriate course of action will perhaps be the deployment a vaccine-based approach, although shorter term responses are likely to include repurposing of existing therapeutics and dusting down of respiratory-medicine kit (i.e. respirators). In terms of vaccines, the scramble has already started, with the University of Queensland generating a preclinical candidate in just three weeks. The Davos public-private founded

Coalition for Epidemic Preparedness Innovations (CEPI) has an ambition of using innovative platforms to generate vaccines in just six months. Whilst this is possible, and assuming speedy authorisation by regulators, a vaccine could well have shortfalls, including safety. However, if combined with an effective control strategy that delays transmission rates until summer and therefore reduces the base level of transmission of most airborne disease (via a number of factors including atmospheric conditions), an emergency vaccine could be deployed over 2020/21 as an additional line of defence against a new agent, particularly amongst the most vulnerable (i.e. the elderly and healthcare workers). In addition to the University of Queensland, a number of companies are already working on vaccines and therapies. These include other CEPI-based vaccine collaborations with GSK (immune boosting adjuvants), Curevac (mRNA vaccine) and Moderna/NIAID (mRNA vaccine). Additional programmes have also been initiated by many other companies, including GeoVax (MVA-VLP approach with China-based BravoVax), the Italian companies Takis and Ewivax (antibody-based approach) and Regeneron/ US Department of Health (antibody-based therapy). In the UK we might expect the likes of the University of Oxford (rich in vaccine expertise) to contribute to development of a vaccine, with perhaps the Vaccines Manufacture Innovation Centre (VMIC) at Harwell fast-tracked to provide longer-term support. We also note a potential role for 'new vaccine players within the Oxford cluster to play a role at some point. These include Enesi Pharma, with its potential for highly thermostable, single-shot, needleless, non-adjuvanted vaccine technology, which offers potential benefits in terms of efficacy, safety AND logistics. Despite some scepticism that new programmes will be sufficiently timely, we believe it is likely that expected novel therapies and vaccines will be generated in sufficient time to have a material effect on the longer-term transmission, morbidity and mortality associated with SARS-CoV-2. We note that further 'waves' of the infection, perhaps annually, are a possibility. Perhaps more importantly these efforts, although in their infancy, are even likely to will undoubtedly provide the basis for new innovative and regulatory responses to potentially much more worrying future infections. In the meantime, the spread of COVID-19 will continue to (i) test our existing public health systems and (ii) demand a response from the innovators amongst us in terms of diagnostics, critical care, pharmacotherapy and prophylaxis.



Supporting The Life Sciences Industry

Join Today

Membership of the OBN Network provides:

- Access to high quality networking opportunities
- Discounted rates to high profile industry events
- The opportunity to use our purchasing consortium offering the best available discounts
- Tailored advice and professional support
- Targeted professional training courses
- Representation of your organisations' interests to a national and international audience

For more information contact
Nicola Westgate, Membership Manager
nicola.westgate@obn.org.uk

www.obn.org.uk



OBN Members Directory

OBN's Corporate Membership of 400-plus organisations includes many R&D companies (therapeutic, medical technology and diagnostics) as well as an extensive range of contract research (CRO) and manufacturing (CMO) organisations, companies in the associated industries and specialist suppliers.

The listing below shows our Member companies arranged by sector.

Therapeutics Discovery and Development

Absynth Biologics

www.absynthbiologics.co.uk

Discover and develop vaccines and antibodies to prevent and treat bacterial infections

Activatec

www.activatec-bi.com

Focus on the evaluation of processes for the manufacture of active biobased compounds and ingredients for nutraceutical and cosmetics products from currently unused and low-value organic sources

Adaptimmune

www.adaptimmune.com

A clinical-stage biopharmaceutical company focused on the development of novel cell-based cancer immunotherapy products

Antikor Biopharma

www.antikor.co.uk

Developing innovative antibody fragment-drug conjugates for improved tumours treatments. The company's proprietary lysine-based conjugation platform, OptiLink™, enables high payload loading of the antibody fragment, more effective penetration of tumours and rapid clearance from normal tissue

Areacor

www.areacor.com

Developing a portfolio of proprietary products that will enable improved treatments for diabetes via the reformulation of approved proteins and peptides

Ascension Healthcare

www.ascension.co.uk

A clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis

BenevolentAI

www.benevolent.ai

Focus on bringing together artificial intelligence technology and scientific research to enable the more rapid creation of better medicines

Bioarchitech

www.bioarchitech.com

Developing oncolytic viruses for cancer treatment

Blueberry Therapeutics

www.blueberrytherapeutics.com

A drug discovery and development company, engaged in the development of therapies to treat infectious and inflammatory diseases

Celixir

www.celixir.com

A regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need

CHAIN Biotechnology

www.chainbiotech.com

Focused on the development of its Clostridia-based proprietary CADD™ platform for delivery of therapeutics and vaccines to the lower gastrointestinal tract

Chronos Therapeutics

www.chronotherapeutics.com

A CNS specialist company developing therapeutics for degenerative and behavioural diseases of the brain and nervous system

CIMYM BioSciences

Provide consultancy services for development of drugs and diagnostics

CN Bio Innovations

www.cn-bio.com

Develops human organ-on-chip technologies and devices that enable the formation of miniature models of human organs which can be used in the drug discovery and development process

Crescendo Biologics

www.crescendobiologics.com

An oncology-focused drug discovery and development company using its proprietary Humabody™ VH technology to develop novel targeted T-cell engaging therapeutics

DJS Antibodies

www.djsantibodies.com

Discovery and development of functional antibodies to GPCRs

Eli Lilly & Company

www.lilly.co.uk

A research based global pharmaceutical company with diverse interests including oncology, neuroscience and diabetes and related complications

Emergex Vaccines Holdings

www.emergexvaccines.com

Developing a new approach to vaccine development in order to address some of the immediate health threats, such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria

Enesi Pharma

www.enesipharma.com

A clinical-stage pharmaceutical company focusing on the development of solid dose vaccines and other injectable solid dose drug-device combination products

Ervaxx

www.ervaxx.com

Exploiting novel insights into the expression of human endogenous retroviruses in different cancers to develop a pipeline of first-in-class cancer vaccines

e-Therapeutics

www.etherapeutics.co.uk

A drug discovery company with a proprietary computational drug discovery platform based on advances in network pharmacology and chemical biology

Evox Therapeutics

www.evoxtherapeutics.com

A biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics

Exonate

www.exonate.com

Developing drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need with an immediate focus on alternative splicing of VEGF to treat wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME)

Exscientia

www.exscientia.ai

Is applying its proprietary AI platform to big data to accelerate the drug discovery and design process

Fast Biopharma

www.fastbiopharma.com

Established to address new targets in immuno-oncology. The company's lead product is an optimised antibody against a key oncology target

Grey Wolf Therapeutics

www.greywolftherapeutics.com

Develops immunotherapies that illuminate non-responsive tumors for destruction by the immune system. The company is developing small molecules to target ERAP1 and 2, targets of growing academic interest for multiple cancers

Haemostatix

www.haemostatix.com

Developing and commercialising active clotting agents/haemostats for the control of bleeding

HOX Therapeutics

www.hoxtherapeutics.com/

Developing novel treatments for cancer through targeting HOX family proteins which frequently have aberrant biological activity in tumours

IGEM Therapeutics

<https://igemtherapeutics.com>

An immuno-oncology company focused on developing immunoglobulin E (IgE) antibodies to treat cancer. The lead product for ovarian cancer is in Phase 1/2

ILC Therapeutics (formerly Alfacyte)

<https://www.ilctherapeutics.com/>

Focused on developing new treatments for cancer, atopic dermatitis and psoriasis using novel peptides that modulate the innate immune system

Imophoron

www.unitdx.com/novel-vaccine-technology-interview-fred-garzoni-imophoron

Developing a novel vaccine platform for use on emerging infectious diseases. The platform is based on a single component of the human Adenovirus that spontaneously forms a superparticle, the ADDomer

Innaxon Therapeuticswww.innaxon.com

Working in the area of innate immunity and has lead products in cancer and inflammatory disease. These are the Toll-like Receptor 4 (TLR4) agonists (Dendrophilin® and Novo-Pyrexal®) and an in-licensed small molecule inhibitor (an IAXOTM compound)

Ipsen Bioinnovationwww.ipsen.com/uk/

A global pharma company with three main areas of focus: oncology, neurosciences and rare diseases

Kalvista Pharmaceuticalswww.kalvista.com

A pharmaceutical company focused on the discovery, development and commercialisation of small molecule protease inhibitors as new treatments for hereditary angioedema (HAE), diabetic macular edema (DME), and other plasma kallikrein-associated diseases.

Karus Therapeuticswww.karustherapeutics.com

Designs and develops small-molecule drugs that combine targeted therapy and immunotherapy activity for the effective treatment of a diverse range of solid and hematological cancers

Locate Therapeuticswww.locatetherapeutics.com

A specialist regenerative medicine and device company which has developed TAOS™ a patented platform polymer technology with multiple medical applications

Macrophage Pharmawww.macrophagepharma.com

Is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses

Macrophox

A newly founded company engaged in research and experimental development on biotechnology

metaLinearwww.metaLinear.co.uk

metaLinear is active in discovering novel targets for anti-bacterial drugs and antibiotic re-sensitisers through proteome engineering

MiroBio<http://www.mirobio.com/>

A 2019 OUI spinout working on treatments for autoimmune and inflammatory disorders

Nanomericswww.nanomerics.com

Mainly develops drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides using proprietary pharmaceutical nanotechnology

NanOptima**None**

Is a biotechnology startup based in Alderley Park BioHub developing novel formulations that include peptidic hydrogel and/or nanoparticle technologies to improve ophthalmic drug delivery

NestTeckwww.biocity.co.uk/company/nestteck/

Developing environmentally responsible antimicrobial and insecticide technologies for a range of industrial and consumer applications, including the veterinary, industrial and healthcare sectors

Neuro-Biowww.neuro-bio.com

Involved in drug discovery and development in the area of degenerative brain disease. Their unique strategy has produced a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration

NeurocentRx Pharmawww.neurocentrx.com

Is a collaborative biotech company, which focuses on developing medicines to alleviate severe and chronic neuropathic pain experienced by cancer patients

Novo Nordiskwww.novonordisk.com

A global pharma with diverse interests particularly in the area of diabetes and associated diseases

Nucleomewww.nucleome.com

Developing therapeutics based on a proprietary 3D nuclear architecture and AI powered computational genomics drug discovery platform

NuVision Biotherapieswww.nu-vision.co.uk

Established to commercialise biotherapies for treating 'front of the eye' disease and trauma

OMass Therapeuticswww.omass.com

Focused on structural mass spectrometry to discover novel medicines

Orbit Discoverywww.orbitdiscovery.com

Utilises its proprietary display platform to identify robust peptide drug candidates for internal industry drug discovery programs and via collaborative research

Ossianixwww.ossianix.co.uk

Developing biotherapeutic products based on the single domain VNAR antibody from the shark. Current programs focus on autoimmunity, neurodegeneration, ALS, pain and botulism

Oxford BioMedicawww.oxb.com

Is a gene and cell therapy company focused on developing life changing treatments in the areas of oncology, ophthalmology and CNS disorders

Oxford BioTherapeuticswww.oxfordbiotherapeutics.com

A clinical stage biotechnology company developing a range of antibody based therapeutics for the treatment of cancer

Oxford Vacmedixwww.oxfordvacmedix.com

Developing therapeutic agents for the treatment of cancer based on Recombinant Overlapping Peptides (ROPs)

OxSonics Therapeuticswww.oxsonics.com

Developing an ultrasound based platform to enhance the delivery of anti-cancer agents to tumours by disrupting the structure of the tumour

OxStemwww.oxstem.co.uk

A drug discovery company with the vision of developing in-situ cell re-programming therapies to treat dementia, heart failure, macular, diabetes and oncology

Oxularwww.oxular.com

Developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases

Pedanius Therapeuticswww.pedaniustherapeutics.com

Developing RNAi therapies for Gram-negative bacterial infections

PepGen

Developing cell-penetrating peptides for treatment of muscular dystrophies

Phylo Biosciencewww.phylos.bio

A plant biotech company aiming to apply genomics and statistics to revolution the future of cannabis

Platelet Serviceswww.plateletsolutions.co.uk

Provides products and services for platelet function testing which is useful for diagnosis of abnormal bleeding and to monitor platelet function in those who are at-risk of cardiovascular events

Precision Medicineswww.precimed.com

Focuses on in-licensing innovative drug candidates which are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use

Precision NanoSystemswww.precisionnanosystems.com

Working on the discovery, development, and manufacture of novel nanoparticle medicines

ProFactor Pharmawww.profactorpharma.com

Develops, commercialises, and supplies recombinant blood factors for the treatment of haemophilia

PsiOxus Therapeuticswww.psioxus.com

Focused on discovering and developing gene-based immuno-oncology treatments for solid tumors using its proprietary intravenously administered T-SiGn virus platform

Redx Pharmawww.redxpharma.com

Focuses on the development of small molecule therapeutics in particular for cancer and fibrosis

Replimunewww.replimune.com

Develop novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released

Scancellwww.scancell.co.uk

Scancell is focused on developing a pipeline of DNA-based cancer immunotherapies that encode a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells

Sigma Aldrich/Merckwww.sigmaaldrich.com

Is a leading global life science and high technology company with their products being used worldwide to enable science that improves the quality of life

Silence Therapeuticswww.silence-therapeutics.com

Is an siRNA company with interests in diverse areas including beta thalassemia, myelodysplastic syndrome and cardiovascular disease

Sitryx Therapeuticswww.sitryx.com

Is a biopharmaceutical company focused on regulating cell metabolism to develop disease modifying therapeutics in immuno-oncology and immuno-inflammation

Summit Therapeuticswww.summitplc.com

Focus on the discovery, development and commercialisation of novel medicines for bacterial diseases

Theolyticswww.theolytics.com

Is a start-up biotech company focused on development of oncolytic viral therapies

TopiVert Pharmawww.topivert.com

Is developing next-generation, Non-Systemic Kinase Inhibitors (NSKIs) as novel medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye

Twist Biosciencewww.twistbioscience.com

Is a synthetic biology company that manufactures and sells synthetic DNA-based products.

UCB Pharmawww.ucbpharma.co.uk

Is dedicated to the research, development and commercialisation of medicines with a focus on the diseases of the central nervous system (CNS) and immunology disorders

Vaccitechwww.vaccitech.co.uk

Develop leading T cell-inducing vaccine products to improve global health. It is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications

Valo Therapeuticswww.valotx.com

Developing cancer therapies using the PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) platform which combines two clinically proven cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine, to take advantage of the best features of both technologies

Vertex Pharmaceuticals (Europe)www.vrtx.com

Is a biotechnology company committed to the discovery and development of small molecule drugs for serious diseases. Has a very strong pipeline in cystic fibrosis but also has interests in pain and haemoglobinopathies

Viatemwww.birminghamresearchpark.co.uk/tenants/viatem-ltd

Aiming to develop the potential of peptimem, a short peptide, that plays a role in controlling inflammation

Other Biotechnology**Abingdon Health**www.abingdonhealth.com

A diagnostics group, working across multiple industry sectors, developing, manufacturing and commercialising lateral flow immunoassay tests and reader system internally and for contract customers

Accentus Medicalwww.accentus-medical.com

Develop novel surface technologies to address the challenges of implantable medical device design and performance

Accuneawww.accunea.com

A point-of-care diagnostics company which combines a small bedside bioanalytical system with artificial intelligence to enable the continuous and real-time monitoring of a patient's kidney function

Advanced Molecular Diagnosticswww.am-diagnostics.co.uk

A molecular diagnostics company that develops, manufactures and supplies molecular diagnostic instruments, kits and consumables

Anaphitewww.anaphite.com

Developing a nanomaterial ('Anaphite') that is a combination of graphene and anastase. The nanocomposite is a photocatalyst that can be used for air purification and battery technology

APA Parafrictawww.parafricta.com

A wound care company which markets a range of skincare products made from its proprietary, low-friction fabric, Parafricta®

Blue Earth Diagnosticswww.blueearthdiagnostics.com

A molecular imaging diagnostics company focused on the development and commercialisation of novel PET imaging agents to inform clinical management and guide care for cancer patients

Cambridge Respiratory Innovations (CRiL)www.criltd.co.uk

Develop innovative medical devices to diagnose and manage respiratory conditions

Carbometricswww.carbometrics.com

Using proprietary Biomimetic Glucose Binding Molecules (GBM) to develop a new glucose sensor chemistry that will enable market-leading Continuous Glucose Monitors (CGM)

Cernotaswww.cernotas.com

Is developing a new microbiology testing platform capable of determining the presence of microorganisms

Cytox Groupwww.cytoxgroup.com

Developing transformational prognostic technology that may contribute to the assessment of an individual's risk of developing dementias such as Alzheimer's disease and which can also be used to identify patients suitable for inclusion in clinical trials

DynamX Medicalwww.dynamxmedical.com

Developing a diagnostic system that distinguishes between cancerous and pre-cancerous tissues biopsies. The system combines commercially-available hardware with their patent-pending data analysis method to provide a rapid system for screening biopsies at the point-of-care

Edinburgh Molecular Imagingwww.edinimage.com

A clinical phase biotechnology company focused developing imaging agents that can be used to detect diseased tissue in real-time with the potential for use during interventional procedures including surgery

Endomagwww.endomag.com

Produce diagnostic technology for more effective breast cancer localisation within breast tissue and sentinel lymph nodes thereby help women with breast cancer avoid surgery when it isn't needed, and experience better outcomes when it is

Enlight Medicalwww.enlightmedical.com

Translate complex scientific ideas into eye-catching, easy-to-understand 3D animations, using state-of-the-art computer-generated imagery and virtual reality tools, to help you communicate the science behind your brand to broader audiences

FluoretiQwww.fluoretiq.com

Developing a rapid diagnostic platform for detection of bacteria at the PoC. Their platform is based on advances in glycan chemistry and quantum optics

Future Geneticswww.futuregenetics.co.uk

A non-profit focused on the discovery and development of disease biomarkers in areas of unmet clinical need

Genomics plcwww.genomicsplc.com

A genome analysis company building analytical platforms for optimising genome sequencing and integrating DNA data with diverse biological information to enable better discovery of new drug targets and to deliver precision health

GM Scientificwww.linkedin.com/company/gm-scientific/about/

Specialises in the distribution and marketing of innovative healthcare products

Hutano Diagnosticswww.linkedin.com/company/hutano-diagnostics/

A start-up developing a diagnostic and surveillance platform for diseases caused by emerging and dangerous pathogens which cause recurring epidemics in Africa

Inivata<https://www.inivata.com/>

A global clinical cancer genomics company. Its InVision® platform unlocks essential genomic information from a simple blood test to help realise personalised care for cancer patients

Iota Scienceswww.iotasciences.com

Are pioneering the development of technologies that facilitates the rapid shaping of liquids on surfaces used to maintain and analyse cells, i.e. polystyrene and glass

Isansys Lifecarewww.isansys.com

Developing and commercialising wireless monitoring devices and systems for real time and predictive indications of patient status in the hospital and home setting

Manchester BIOGELwww.manchesterbiogel.com

Developing biocompatible and biodegradable graft materials that provide the ideal matrix for implanted cells to carry out tissue repair and regeneration

Medherantwww.medherant.co.uk

A clinical-stage company developing drug-in-adhesive patch products for pain and CNS diseases based on their TEPI® technology in combination with already approved drugs

MediSievewww.medisieve.com

Developing a magnetic particles based technology to remove unwanted substances from a patient's blood stream. Key projects are malaria, leukemia and sepsis

MiRNA Diagnosticswww.mirnadiagnostics.eu

A biotech startup developing microRNA biomarkers for use in molecular neuroscience

Mologicwww.mologic.co.uk

A CRO working in the diagnostics space. It offers services in the research, development and manufacture of lateral flow based in vitro diagnostic devices

Momentum BioSciencewww.momentumbio.co.uk

Develops rapid tests for critically-important clinical specimens within the hospital microbiology laboratory

NuNanowww.nunano.com

A UK-based company specialising in the design and manufacture of probes for atomic force microscopy and cantilever-based sensor devices

Onca XTwww.oncaxt.com

Developing a unique type of blood test for cancer which, used in conjunction with existing methods of screening and diagnosis, could improve their accuracy of diagnosis

Orthoxwww.orthox.co.uk

Developing a range of novel orthopaedic products for the repair of knee cartilage formed from FibroFix™, a patented, biomaterial with a molecular structure, strength and resilience that emulates human knee cartilage

Oxford Cancer Biomarkerswww.oxfordbio.com

Developing a suite of drug-specific companion diagnostic tests using its predictive biomarker technologies CancerNav®

Oxford Endovascularwww.oxfordendovascular.com

A medical device company developing a next generation flow-diverter for the minimally invasive treatment of intracranial aneurysms which cause death or disability due to brain haemorrhage

Oxford Gene Technologywww.ogt.co.uk

Provides genetics research solutions to clinical and academic research institutions

Oxford Immunotecwww.oxfordimmunotec.com

A global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology

Oxford Nanopore Technologieswww.nanoporetech.com

Developing a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins

Renovos Biologicswww.renovos.co.uk

Is commercialising the research undertaken at the University of Southampton on skeletal stem cells, translational orthopaedic research and materials for tissue repair

Rosa Biotechnologywww.rosabio.tech

Is developing new sensing devices that mimic the properties of the olfactory systems of mammals. The key components are self-assembling peptide barrels capable of binding a huge range of analytes and these are linked to a colorimetric measurement system

Safeguard Biosystems Holdingswww.sgbio.com

Commercialising molecular diagnostic technologies and tests for mass surveillance and selective screening for pathogens and other agents for agriculture, food safety, genetic screening and human health applications

Sharp Life Science (EU)www.aqdrop.com

Is a medical device company that is developing the aQdrop lab-on-a-chip microfluidic technology platform (<https://www.aqdrop.com/>) lab-on-a-chip which offers advances in accuracy, quality and reliability in genomics, proteomics and other areas

The Electrospinning Companywww.electrospinning.co.uk

Design, develop and manufacture materials for use in regenerative devices and in 3D cell culture

Ultromicswww.ultromics.com

Developing an AI-driven software platform that provides increased diagnostic capabilities to echocardiography equipment to improve the diagnosis of coronary heart disease

VivoPlex Medicalwww.vivoplex.com

Is developing an innovative monitoring device to measure dissolved oxygen (DO), pH and temperature in the uterus of women seeking medical help to improve their fertility

Invizius<https://www.invizius.com/>

Developing a coating for kidney dialysis membranes that prevents activation of the immune system and its undesirable effects on the patient

Spintex Engineeringwww.spintex.co.uk

Spintex, a spin out from the University of Oxford, manufactures pure and tough silk fibres and materials for medical devices and regenerative medicine

Sense Biodetection Limitedwww.sense-bio.com

Developing a range of point of care diagnostics

SeraScience Limited<https://www.abingdonhealth.com/medical-diagnostics/seralite/>

SeraScience operates as a part of Abingdon Health. They work in the diagnostic space and have a lead product 'Seralite' for detection of multiple myeloma

Intelligent OMICS<http://www.intellomx.com/>

Using an in house data analysis algorithm to identify patterns in healthcare datasets to find new disease markers and drivers of disease pathways that will lead to new diagnostic tools and targeted therapies

Aliksirwww.aliksir.co.uk

Develop sensor systems to drive improvements in water quality testing

Azotic Technologieswww.azotictechnologies.com

Their natural nitrogen fixing technology, which is based on a food grade bacteria, provides a sustainable solution to fertiliser overuse and nitrogen pollution

Crysalinwww.crysalin.com

Developing a protein lattice nanotechnology to assist in formation of crystals of macromolecules for use in X-ray and EM structure determination studies

Folium Food Sciencewww.foliumscience.com

Developing 'Guided Biotics' to alter the composition of complex microbiomes. Applications envisaged include removal of undesirable bacteria from animals and plants and from the environment and food

Green Biologicswww.greenbiologics.com

A renewable chemicals company focused on developing and delivering new green alternatives for everyday products providing clients with more sustainable products compared to petroleum-based alternatives

Jellagenwww.jellagen.co.uk

Offer high grade native collagen sourced from jellyfish. This is applicable for tissue engineering, regenerative medicine, stem cell research and a wide variety of cell culture application

MOA Technologywww.moa-technology.com

Aim to discover the next generation of sustainable herbicide chemistries with new modes of action from both natural and synthetic sources

Naturally Scientific Energywww.naturally-scientific.com

Produces natural oils for the nutritional and personal care end markets

Worn Again Technologieswww.wornagain.co.uk

Pioneering polymer recycling technology that can separate, decontaminate and extract polyester polymers, and cellulose from cotton, from non-reusable textiles and PET bottles and packaging and turn them back into new textile raw materials as part of a continual cycle

Biotech**GyreOx Ltd**www.gyrex.com

GyreOx's proprietary discovery platform creates unique 'Gyrocycle' highly modified macrocyclic peptides, which combine the target-engagement power of biologics with the cell-entry ability of small molecules

Carocell Biowww.carocellbio.com

Carocell Bio is developing novel combination medicines for serious inflammatory conditions, including atopic dermatitis, inflammatory bowel disease and burns

Pathios Therapeuticswww.pathios.com

Pathios Therapeutics is an early-stage drug discovery company pursuing novel small-molecule drugs that target acid-sensing GPCRs on cells of the adaptive and innate immune systems

Polymaths AItwitter.com/polymathsai

An Oxford University spinout developing and providing AI augmented model-informed drug discovery and development services

Oncimmune<https://oncimmune.com/>

Oncimmune is developing early cancer detection technologies for more effective disease management

Cumulus Oncology Ltd<https://www.cumulusoncology.com/>

Cumulus is developing novel anti-cancer therapies

Sporegen Ltd<http://sporegen.com/>

Sporegen is working on a number of products including the development of vaccines based on Bacillus subtilis

Hairclonewww.hairclone.me

Working to develop hair rejuvenation and regeneration treatments

Mironid<https://www.mironid.com/>

Developing new medicines for degenerative kidney diseases, chronic inflammatory diseases and cancer

Oxgene<https://www.oxgene.com/>

Developing a range of technologies to enable precise and robust mammalian cell engineering to enable more rapid development of gene therapies, antibody-based therapeutics and CRISPR / gene editing

CytoSeekwww.cytoseek.uk/

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing

CXO/Consultant

A4Pbiowww.a4pbio.com

Delivers expertise in the selection, use, interpretation and bioanalysis of clinical biomarkers and pharmacokinetics across multiple therapeutic areas by engagement and management of CRO suppliers for pre-clinical and clinical studies

Abzenawww.abzena.com

Offer a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals products based on antibodies or other proteins

Aigenpulsewww.aigenpulse.com

A data management and analytics platform for scientific data generated within the field of life sciences

Alan Boyd Consultantswww.boydconsultants.com

Provide specialist consulting services for pharma and biotech companies to support their research activities and drug development

Alderley Analyticalwww.alderleyanalytical.com

Offer specialist bioanalytical services to support drug development programmes, from discovery through to late stage clinical development, focusing on small or large molecules, peptides and biomarkers

Antibody Analyticswww.antibodyanalytics.com

Provide innovative solutions for the effector function characterisation of therapeutic antibodies with a specific focus on biosimilars

ApconiXwww.apconix.com

An integrated toxicology and ion channel company at the forefront of nonclinical toxicology and safety science related to ion channels in particular

Apex Healthcare Consultingwww.apex-consulting.co.uk

An analytical healthcare consultancy which provides strategic business evaluations and analysis the healthcare sector in Europe and the US

Apex Molecularwww.apexmolecular.com

A Synthetic chemistry company providing specialist services for the pharmaceutical, biotechnology and applied chemical sectors

Aptus Clinicalwww.aptusclinical.com

Provide a range of services including full clinical study design, oversight and delivery and individual consultancy projects

Aquila BioMedicalwww.aquila-bm.com

Aquila BioMedical is a preclinical contract research organisation, offering clients world-leading research expertise in immunology, immunology and multiplex histology

Arcinovawww.arcinova.uk

A CDMO that provides a comprehensive range of services including process, research, development, scale-up and small scale manufacturing

Arctoriswww.arctoris.com

Provides a range of automated/roboticised services to support drug discovery and development particularly within oncology

Athena Market Access Solutionswww.athenamarketaccesssolutions.co.uk

Specialise in providing pricing and reimbursement related solutions to organisations in the life sciences industry

Aurelia Biosciencewww.aureliabio.com

Provide services in biological assay development, biological screening and laboratory equipment consultancy to SMEs, universities, medical charities, pharmaceutical companies and screening equipment manufacturers

Ayva Clinical Serviceswww.ayvaclinicaltrials.com

Offer a global comparator service for drug procurement and supply

BioAscent Discoverywww.bioascent.com

Has extensive capabilities encompassing medicinal chemistry, computational chemistry, in vitro biosciences, DMPK, compound management

BioConnectionwww.bioconnection.eu

A contract services and manufacturing organisation for the development and manufacture (filling and freeze drying) of injectable (bio)pharmaceutical products

BioDividewww.biodivide.com

Aim to transform the regenerative medicine field by addressing challenges in the complete workflow from stem cell harvest, manufacture, cryostorage to clinical administration

Biomedhawww.biomedha.com

A CRO offering a range of pre-clinical drug development services to clients in biotech, pharma and virtual companies as well as spin-outs and academic institutions

BioPharma Stability Testing (BSTL)www.biopharmastabilitytestinglaboratory.co.uk

Perform analytical and biological testing services and provides access to high throughput analytical and bio-analytical testing equipment

BioPharmaLogicwww.biopharmalogic.com

Offer services to facilitate all aspects of nonclinical drug development

Biorelatewww.biorelate.com

Provide biomedical research services based on their Galactic AI platform that unifies data processing, querying, deep learning and investigation

C4X Discoverywww.c4xdiscovery.com

Exploits cutting edge technologies to design and create small-molecule candidates in a range of therapeutic areas

CatSciwww.catsci.com

A process research and development CRO working in the drug discovery and development area

Celentyxwww.celentyx.com

A CRO offering bespoke assay services in human immunology, including immuno-oncology, autoimmunity and inflammation, fibrosis and neuroinflammation

Cello Health Consultingwww.cellohealthconsulting.com

Focuses on the Healthcare industry (RX / OTC & Animal Health) helping companies unlock the potential of organisations, people, assets and brands

Cellomatics Biosciences Ltdwww.cellomaticsbio.com

Provides expert preclinical in vitro services within oncology/immunology, immunology/inflammation and respiratory therapeutic areas

CEM Analytical Services (CEMAS)www.cemas.co.uk

A contract analytical company specialised in generating registration data on behalf of the pharmaceutical, agrochemical and biocides industries

Centre for Process Innovation (CPI)www.uk-cpi.com

Helps companies to develop, prove, prototype and commercialise next generation products and processes

Charnwood Molecularwww.charnwood-molecular.com

Provide medicinal and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries

Cobra Biologicswww.cobrabio.com

A CDMO providing biologics and pharmaceuticals for clinical and commercial supply

Covance Laboratorieswww.covance.com

Provide nonclinical, clinical, and commercialisation services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development

CRA International<http://www.crai.co.uk/industry/life-sciences>

A global consultancy serving diverse sectors including the life sciences

Cripps Clinical Consultingwww.crippsclinical.com

Specialise in selection and oversight of European service providers to support client's clinical development programmes

Cytera CellWorkswww.cytera.bio

Developing technology for automation of cell culture

Data Magikwww.datamagik.co.uk

Offer a full clinical trial design and management service, including a complete range of statistical and data management support services

Diamond Pharma Serviceswww.diamondpharmaservices.com

Diamond Pharma Services is a technical services and consulting group, providing expert support and advice to pharmaceutical and biotechnology companies with expertise in the cell and gene therapy space. Their three core areas are regulatory affairs, pharmacovigilance and compliance

Diligent Business Consultingwww.diligentglobal.com

Assist clients with various industry related projects, including outward and inward licensing, and supporting early/mid-stage companies wishing to become investor ready

Drug Discovery and Development Consultantswww.3dconsultants.org.uk

Drug discovery and development consultants provide support and advice across all aspects of drug discovery and development, in-licensing or out-licensing of assets or technologies, as well as preparation of business plans and identifying/presenting to potential investors

ERA Consulting UKwww.eraconsulting.com

A regulatory affairs and product development consulting groups serving the biopharmaceutical industry. Their services covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective

EUDRACwww.eudrac.com

A specialised regulatory affairs consultancy company providing support to drive products through development, registration, market launch and post-approval activities across all EU countries

Eurofins Pharma Discovery Services UKwww.eurofins.com

A contract research organisation that provides drug discovery services to pharma and biotech companies worldwide

Excellerate Biosciencewww.excelleratebio.com

Provide molecular pharmacology services to drug discovery companies, specialising in kinetic assay design and ligand characterisation

Food and Drug Analytical Services (FDAS)www.fdas.org

A contract testing laboratory, providing independent, GMP analytical services. The company's MHRA-accredited laboratories offer a full range of analytical methodologies, ICH stability storage, development and validation expertise

Gentronixwww.gentronix.co.uk

A biotechnology service company offering early screening, mechanistic follow-up and regulatory genotoxicity assays for a range of industries including pharmaceuticals, chemicals, agrochemicals, personal care, consumer products, flavours, fragrances and taste enhancers

Gifford Biosciencewww.giffordbioscience.com

A preclinical CRO providing receptor occupancy studies, radioligand binding assays and autoradiography

HC Pharma Consultancywww.helencohen4.wixsite.com/hcpharma

Provides personal guidance and support to pharma and biotech for all partnering activities for pharma products; developing partnering strategies, leading out-license campaigns, in-license searches, due diligence, negotiation of contracts or management of alliances

Hematogenix Laboratory Serviceswww.pharma.hematogenix.com

A GCP compliant and CAP and CLIA certified laboratory offering clinical trial biomarker services including flow cytometry, FISH, IHC, mRNA ISH, PCR, sequencing, and many more

HistologiXwww.histologix.co.uk

A privately owned GLP/GCP accredited contract research organisation that provides pathology services for the pharmaceutical and biotechnology industry. They provide human tissue based solutions in support of regulatory preclinical programmes, clinical trials in addition to biomarker projects

Horizon Discoverywww.horizondiscovery.com

Provide a range of services to support drug discovery including functional genomics and high throughput screening using sophisticated CRISPR generated lines, animal models and gene editing (using CRISPR technology)

Imagen Therapeuticswww.imagentherapeutics.com

Provide a complete high content screening service for large pharma and small biotech. The company offers a wide range of image-based assays including neuronal, angiogenic, cellular signalling, and other complex morphological assays.

InClinicawww.inclinica.com

A global clinical CRO that specialises in leading companies through clinical trials and applying their in-depth experience and expertise in clinical research and drug development

Invicrowww.invicro.com

An imaging science company that provides advanced data analysis services and software in the growing field of pre-clinical imaging research

Invivo Clinical T/A Bionomicswww.invivoclinical.co.uk

A healthcare company that offers the latest advancements in bioscience, diagnostics and therapeutics to healthcare practitioners and their patients

Jon Rees Associateswww.jonreesassociates.com

A specialist consultancy with a focus on the interface between investment and innovation.

Kaleidoscope Consultantswww.kaleidoscopeconsultants.com

Data privacy consultants

Kelyonwww.kelyon.com

An ICT company which specialises in the design and development of software medical devices, web and mobile applications based on open source technologies, for big pharmaceutical companies, medical-scientific associations, and healthcare facilities

Leaf Expression Systemswww.leafexpressionsystems.co.uk

A CDMO specialising in plant-based expression systems and the production of custom proteins

Lonza Biologicswww.lonza.com

Operates as a contract manufacturer of monoclonal antibodies and recombinant protein and engages in protein engineering, viral testing, toxicology studies, and clinical trials.

Ludgerwww.ludger.com

Specialises in analytical technology for medical applications of glycobiology and manufactures a comprehensive range of kits and reagents for ICH-compliant glycoprofiling of biopharmaceuticals throughout the drug development cycle

Manentiawww.manentia.co.uk

Is a full service CRO that delivers clinical development service for whole programmes or individual projects

Menarini Biotech UKwww.menarini-biotech.com

A CDMO that provides expertise in production of biosimilars, innovative monoclonal antibodies and other recombinant proteins

myClin Europewww.myclin.com

Offers a clinical oversight platform that allows users to share documents efficiently, improve engagement and stay audit-ready at all times

Oxford Expression Technologieswww.oetltd.com

A contract organisation with expertise in baculovirus protein expression

Patheon, part of ThermoFisherwww.patheon.com

Patheon, now part of ThermoFisher, provides drug development and manufacturing services to the ThermoFisher group and works in close association with Fisher Clinical Services

Peak Proteinswww.peakproteins.com

Provides protein supply and structure based drug discovery services to clients

Pharmaronwww.pharmaron.com

Is an R&D service provider supporting a wide range of services, from early discovery to clinical development

Pharmidex Pharmaceutical Serviceswww.pharmidex.com

Provide translational solutions using its expertise in CNS/oncology/respiratory, DMPK, drug discovery and ADMET/pharmacokinetics

Phosphonicswww.phosphonics.com

Developing custom and off-the-shelf technologies for removal or recovery of traces of a wide range of metals in product, process or waste stream. Applications in pharmaceutical preparation and chemical production

Physiomicswww.physiomics-plc.com

Provide outsourced systems and computational biology services to pharmaceutical companies including Virtual Tumour, Virtual Tumour Preclinical and services to predict cardiac toxicity

Precision for Medicine, Oncology and Rare Diseasewww.precisionmedicinegrp.com/pfmord/

An oncology specialty CRO that provides clinical research services and application of metrics-driven project management to optimise oncology drug development

Prolimmunewww.proimmune.com

A life science company providing solutions for preclinical and clinical immunology research

Q3 Analyticalwww.bioanalysisforresearch.com

Provide non-regulated bioanalytical support for small pharmaceutical companies carrying out drug discovery and research and also analyse in-vitro samples generated by the client's own in-house biological assays

Reach Separationswww.reachseparations.com/

Specialise in chromatography techniques for the analysis and purification of small molecules, offering screening, method development and purification for chiral and achiral molecules

RenaSciwww.renasci.co.uk

Provide highly specialised consultancy and preclinical experimental services to the global pharmaceutical industry in the areas of abuse and dependence, CNS, obesity, diabetes, NASH and kidney disease

Rockpool Bioscienceswww.rockpoolbio.com

Provides genomics and AI consultancy services

Roylance Pharmawww.roylancepharma.com

Are stability storage specialists offering outsourced sample storage facilities, equipment and validation services

RSSLwww.rssl.com

Provide analytical, investigational, consultancy and training services to clients in the global biopharmaceutical, pharmaceutical and healthcare industries

S-cubedwww.s-cubed.co.uk

S-cubed provides consultancy and support services to pharmaceutical and healthcare clients across a comprehensive range of regulatory, quality assurance and biometrics activities

Seda Pharmaceutical Development Serviceswww.sedapds.com

Seda Pharmaceutical Development Services provide pharmaceutical development and clinical pharmacology services and consultancy to the pharma and biotechnology industry

Syneos Healthwww.syneoshealth.com

Use their Biopharmaceutical Acceleration Model to assist clients with clinical and commercial development

SynteractHCRwww.synteracthcr.com

A full-service CRO that supports pharmaceutical, biotechnology and medical device companies in all phases of clinical development, across multiple therapeutic areas

Tetrad Discoverywww.t4bio.com

A CRO providing bespoke bio-analysis solutions tailored and integrated to the sponsors requirements, using state-of-the-art technologies

Theradex (Europe)www.theradex.com

Offer regulatory and clinical trial management, clinical trials monitoring services, and QA/auditing

Transcrip Partnerswww.transcrip-partners.com

Provide support for the development and lifecycle management of biopharmaceutical products in the field of oncology, respiratory, internal medicine, and CNS

Upperton Pharma Solutionswww.uperton.com

Is a research and development company that specialises in the formulation and spray drying of pharmaceutical and biotechnology products

Vivonics Preclinicalwww.vivonics-preclinical.com

Is a CRO providing preclinical services and consultancy to the biotech and pharmaceutical industry

Williamson Biotech Solutionswww.williamsonbiotechsolutions.com

Offer facilitating services to biotech, medtech, pharma and academic institutions delivering communication, marketing and business development services

Wuxi AppTecwww.wuxiapptec.com

A pharmaceutical, biotechnology, and medical device R&D service provider with operations in China and the United States

XenoGesiswww.xenogesis.com

Specialises in preclinical drug metabolism and pharmacokinetics, quantitative bioanalysis, and data interpretation services

Paras Biopharmaceuticals Finland Oywww.parasbiopharma.com

A Finnish CDMO offering contract development and microbial biologics manufacturing, development and licensing of biosimilars and recombinant bioprocess enzymes

Fidaux Limited

Provide international technology and life sciences senior executive experience, with extensive PLC board level and Public Sector Service. In depth background in licensing, corporate financing, IPO's, M&A and managing strategic change with blue chip companies worldwide

Evotecwww.evotec.com

Evotec is a well established CRO in the drug discovery and development space with European and US presence

Domainexwww.domainex.co.uk

Domainex offers a range of integrated approaches to medicinal chemistry, biochemistry and computational chemistry to assist rapid development of new therapeutics

Kinomica Ltdwww.kinomica.com

Kinomica is a proteomic-data science and diagnostics company specialising in cell signalling. They offer a suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage

Quotient Sciences<https://www.quotientciences.com/>

Provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry

SAL Scientific Limitedwww.salscientific.com

Cell biology specialists providing contract research services and animal-component-free cell culture media supplements to a global client base

Microbial Genomics Ltd (Microbesng)<https://microbesng.com>

Provide a range of Illumina based genome sequencing services

Concept Life Sciences<https://www.conceptlifesciences.com/>

Provide a wide range of services to assist drug development and have particular expertise and success in oncology, anti-infectives, CNS, respiratory, metabolic and cardiovascular.

NDA Regulatory Science<https://www.ndareg.com/>

A leading regulatory and drug development consultancy with a dedicated team of over 150 consultants supported by an expert network and a specialist Advisory Board

Phastarwww.phastar.com

A global CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships

Peppermill Limited

Management consultancy/advisory for the pharma/healthcare sectors

Academic Institutions**Oxford Brookes University**www.brookes.ac.uk

One of the UK's 'modern' universities and provides teaching and innovation as well as strong links with business and industry

Oxford Institute of Biomedical Engineering.www.ibme.ox.ac.uk

Offer a multidisciplinary environment where engineers and clinicians work together on addressing unmet needs in the prevention, early diagnosis and treatment of major diseases and conditions.

Oxford University Innovation (OUI)www.innovation.ox.ac.uk

Is a wholly-owned subsidiary of the University of Oxford and focuses on managing the University's technology transfer and consulting activities.

Queen Mary Innovationwww.qminnovation.co.uk

Queen Mary Innovation Ltd (QMI) is Queen Mary University of London's (QMUL) wholly-owned technology transfer company and responsible for the commercialisation and management of the University's intellectual property and portfolio of spinout companies

Queen's University Belfast Research and Enterprise Directoratewww.qub.ac.uk/Research/Research-contacts/

Help to deliver research and enterprise activities through the development of research strategy and policy.

The Royal Veterinary College Businesswww.rvc.ac.uk/business

The Royal Veterinary College's interface with business and industry

University of Birmingham Enterprisewww.birmingham.ac.uk/enterprise

Supports academics who want to innovate, take their ideas to market, work with businesses and social enterprises, or enrich their professional lives by doing academic consultancy projects.

Warwick Ventureswww.warwickventures.com

Is the technology transfer business unit of the University of Warwick and supports them throughout the process of generating impact and a commercial return from their research.

R&D Support**4T2 Sensors**www.4t2sensors.com

Developing an in-line flow sensor system that can detect concentrations, contaminations and mixtures of fluids

Absolute Antibodywww.absoluteantibody.com

Develop engineered antibodies for the research and diagnostics markets

ACE Cells Labwww.ace-cells.co.uk

A biomolecular lab specialised in providing bioactive peptides and proteins from a range of different cells and tissues

Air Liquide UKwww.uk.airliquide.com

A producer and supplier of industrial and medical gases and related services

Air Productswww.airproducts.co.uk

Provides atmospheric and process gases and related equipment to manufacturing markets and is also a supplier of liquefied natural gas process technology and equipment

AMS Biotechnology (Europe)www.amsbio.com

Specialise in genomics, proteomics, cell culture and stem cell sciences, providing products and custom services for life sciences research

ATG Scientificwww.atgscientific.co.uk

A supplier of laboratory products and equipment solutions to support life sciences research

Aver Decommissioning & Environmentalwww.averdecom.com

A specialist decommissioning and environmental consultancy working across a wide range of industrial sectors in the UK and overseas

Biogelxwww.biogelx.com

A biomaterials company which designs and supplies peptide hydrogels tuned to the requirements of cells to be used for 3D cell culture and bioprinting

Bioline Reagentswww.bioline.com

Develop, manufacture, and market molecular biology reagents

Bio-Rad AbD Serotecwww.bio-rad-antibodies.com

Provide a wide range of reagents, particularly antibodies, for life sciences research

BMG Labtechwww.bmglabtech.com

A leading manufacturer of high-quality, innovative microplate reader instrumentation

Carbosynthwww.carbosynth.com

Offers a comprehensive product range in the fields of carbohydrates and nucleosides for the international life science R&D communities

Fisher Scientific UKwww.fishersci.co.uk

Manufactures and supplies laboratory chemicals and laboratory equipment.

NgaChi

A biotech startup hosted in The Biohub Birmingham and is currently working on the development of a new laboratory consumable

Nonacuswww.nonacus.com

Focus on delivering technologies to the genomic healthcare sector through the use of cell free circulating DNA as a non-invasive diagnostic tool

Oxford Nanoimaging (ONI)www.oni.bio

Bring fluorescence imaging with the greatest level of detail to a new community of researchers, by removing the complications associated with instrumentation, analysis and cost

PeproTech ECwww.peprotech.co.uk

Focus on the development and manufacturing of cytokine products for the life-science and cell therapy markets.

RS Componentswww.uk.rs-online.com/web/

Provides a vast range products, in particular electronic, electrical and industrial components

Thermo Fisherwww.corporate.thermofisher.com

Provide a vast range of consumables, reagents and equipment to the life sciences industry

Tissue Solutionswww.tissue-solutions.com

Is an ISO 9001:2015 accredited provider of high quality human biomaterials for pre-clinical and discovery biomarker research

Tracer Measurement Systemswww.birminghamresearchpark.co.uk/tenants/tracer-measurement-systems-ltd

Provide applications R&D, sales & marketing of mobile chemical ionisation mass spectrometers

PCR BioSystems<https://pcrbio.com/>

Expert in innovative PCR products to support R&D

New England Biolabs (UK) Ltd<https://www.neb.uk.com/>

Provide a wide range of lab reagents and kits to support R&D

2BScientific Ltd<https://www.2bscientific.com/>

Europe's fastest growing distributor of life science reagents

Other**Nexeon**www.nexeon.co.uk

Nexeon® is a battery materials development and licensing company, developing silicon anodes for the next generation of lithium-ion battery

Charity Organisation**The Kirkhouse Trust**www.kirkhousetrust.org

Is a small charity which aspires to improve the food security and livelihood of the rural poor in sub-Saharan Africa and India

The Oxford Trustwww.theoxfordtrust.co.uk

Encourage and facilitates the study, application and communication of science, technology, engineering and mathematics

Investors & Advisors**Akesios Associates**www.akesiosassociates.com

Provides financial strategy, representation and commercial development advice to life science companies.

Cambridge Innovation Capitalwww.cambridgeinnovationcapital.com

An investment fund that invests in high-growth technology companies in diverse sectors

Downingwww.downing.co.uk

Offer management of investment products for investors such as venture capital trusts, enterprise investment schemes, inheritance tax mitigation funds, business premises renovation allowance schemes, and an open ended investment company

G. Knight Consulting

Provides an independent life science strategy and mergers/acquisitions consulting services for private equity and corporate companies

Longwall Venture Partnerswww.longwallventures.com

An Oxford based, venture capital fund management company that specialises in managing early stage investments in science, engineering and technology start-ups

Midvenwww.midven.co.uk

Is a private equity and venture capital firm specialising in start-up, early stage, growth, management buy-outs, and management buy-ins investments in small and medium sized enterprises

Norgine Ventures Managementwww.norgineventures.com

Provide debt and debt-like financing to companies in the fields of healthcare and life sciences, in Europe and the US

Results Healthcarewww.resultshealthcare.com

Provide corporate finance expertise and strategic business advice to the healthcare sector

Seroba Life Scienceswww.seroba-lifesciences.com

Seroba Life Sciences is a European fund manager that invests in the therapeutics and medical devices arena

Silicon Valley Bankwww.svb.com

Provide a full range of financial services to companies of all sizes in innovation centers around the world

SR Onewww.srone.com

Specialise in investing in seed, start up, early and mid venture; and emerging growth companies

SV Health Managerswww.svlsa.com

Is a healthcare and life sciences venture capital and growth equity firm managing over \$2 billion in capital in seven private healthcare funds in the US and Europe

Associated Industry**Activ Business Solutions**www.activ-business.co.uk

Specialise in supplying organisations with a single source solution for all business products, for example, purchasing office furniture, redeveloping a company website, or reviewing office stationery

AggioSergeantwww.aggiosergeant.com

Specialise in life sciences executive search and company culture change.

Alderley Parkwww.alderleypark.co.uk

Offer bioscience facilities for R&D focussed life science companies at every stage of their life-cycle, from start-up to global corporate.

Ardington Archiveswww.ardingtonarchives.co.uk

Provide a range of services in the field of document archiving

Barrington James Board & Executive Partnerswww.barringtonjames.com

Is a global staffing and resourcing organisation that specialises in placing niche consultants at all levels in the biotech and pharmaceutical industry

BDOwww.bdo.co.uk

Global accounting and financial consultancy

BioCity Groupwww.biocity.co.uk

A bioscience incubator, providing the conditions that sustain more than 80 fast-growing businesses. incubator, providing the conditions that sustain more than 80 fast-growing businesses. It has centres in Nottingham, Alderley and Glasgow

BioHub Birminghamwww.thebiohub.co.uk

A fully serviced biomedical research laboratory providing entrepreneurs and innovative start-ups with access to affordable laboratory facilities and equipment

Biotech Personnelwww.biopers.co.uk

An HR consultancy business which specialises in start-up assistance, recruitment, reward management, policy and procedures and culture change programmes

Biotechgatewww.biotechgate.com

Provide a business development database for the life sciences industry

Bulb Laboratorieswww.bulblaboratories.com

Build and furnish commercial interiors from corporate offices to high-tech laboratories

Catalyst Advisors Europewww.catalystadvisorslp.com

A recruiting firm specialising in finding board members, CEOs and senior functional, technical and commercial leaders for biopharmaceutical and other life sciences enterprises at all points of growth

Citigate Dewe Rogerson www.citigatedewerogerson.com

An international public relations firm offering the full range of communications services to companies, both domestically and internationally

Cleveland Scott York <https://www.csy-ip.com/>

A global IP firm

Coulter Partners www.coulterpartners.com

An executive search and management consulting firm assisting healthcare, pharmaceutical, biotechnology, and financial services sectors

Creative Places www.creativeplaces.com

Specialise in creating and shaping business environments that enhance innovation and enterprise, such as Science Parks, Biomedical Campuses, urban areas or Business Innovation Centres

CY Partners www.cypartners.co.uk

Provide recruitment services and advice across the chemical, pharmaceutical, biotech, life sciences and clinical industries

Dehns www.dehns.com

A UK firm of Patent and Trade Mark Attorneys advising on all aspects of patenting innovative technology, registering words, logos and other marks and registering original designs

Destination Cloud www.destinationcloud.co.uk

A next generation Cloud Managed Service Provider, active in the UK and Europe, offering specialist cloud business transformation solutions to businesses

DiagnOx www.diagnox.co.uk

An incubator facility based at the Cherwell Innovation Centre in North Oxfordshire. Owned by Oxford Innovation

EFR Travel www.efrtravel.co.uk

Specialise in corporate travel as well as high end leisure and golfing holidays, private jet travel and a concierge division providing tickets for sold out events. EFR is a provider to the OBN Purchasing Consortium

Elcom Systems www.elcom.com

The world's first cloud-based procurement technology company. They provide solutions for e-invoicing, e-procurement, and e-funding to optimise the clients' Supply Chain processes and are the providers of the OBN Purchasing Platform

Elsevier www.elsevier.com

Provide information and analytics that help institutions and professionals progress science, advance healthcare and improve performance

ESC POWER www.escpower.co.uk

Specialise in UPS backup, power distribution systems and I.T. racks

Ethical Medicines Industry Group (EMIG) www.emig.org.uk

A multi-stakeholder network and trade industry association that represents the interests of the full span of life sciences companies in the UK

Fieldfisher www.fieldfisher.com

A multinational law firm which has practices in sectors including Real Estate, Energy, Financial Services, Government & Public Services, Hotels & Leisure, Life Sciences, Media, Telecoms and Technology.

First Create the Media www.firstcreatethemedia.com

Is a communications consultancy for people that work in science. The company provides consultancy, copywriting, podcast and video production, science communication training and one-to-one coaching

FTI Consulting www.fticonsulting-emea.com

Provide legal tax advice to UK based life sciences companies

Gallagher www.ajginternational.com

Is active in insurance brokerage and risk management providing insurance solutions for a wide range of different businesses including the life sciences

george james www.georgejamesltd.co.uk

Provide European recruitment and global strategic consulting and training services covering the biotechnology, pharmaceuticals, medical devices, diagnostics, instrumentation, scientific software, fine chemicals and chemical technology markets

Greaves Brewster www.greavesbrewster.co.uk

Handles the preparation, filing, prosecution and maintenance of patent, trade mark and design applications

Harwell Campus <https://www.harwellcampus.com/>

Is a science, innovation, technology and business campus and hosts an array of over £1 billion of research infrastructure

Horton International UK www.hortoninternational.com

An executive search firm specialising in the recruitment of senior talent across numerous disciplines

Instinctif Partners www.instinctif.com/uk

Instinctif Partners provides communications consultancy services for science based sectors including corporate, healthcare, and marketing communications, as well as financial communications

Interea International www.interea.co.uk

A provider of middle to senior level interim management to UK and international life science and related companies (biotech, pharma, medical device, diagnostic, regenerative medicine etc.)

Invest Newcastle www.investnewcastle.com

Invest Newcastle provide a range of bespoke, client led support services for potential investors, occupiers and existing businesses making it easy to realise ambitions for growth in Newcastle. The company provides a range of services to potential and existing investors.

JA Kemp www.jakemp.com

Patent and trade mark attorneys

James Cowper Kreston www.jamescowper.co.uk

A firm of accountants and business advisors based in Henley, London, Newbury, Oxford, Reading and Southampton

KISS Communications www.kisscom.co.uk

Is a strategy-led agency that integrates advertising, branding, digital and public relations services, and works with companies in industries such as healthcare, science, technology, research and development

Koi Consulting www.koiconsultants.com

IT technology strategy consulting

Lonestar Strategies www.lonestarstrategies.co.uk

Provide a range of services to help organisations build sustainable competitive advantage and performance improvement through effective individuals and teams

Manchester Science Partnerships www.mspl.co.uk

Focused on the development and management of fit-for-purpose office and laboratory accommodation and the provision of cost effective estate services

Mary Ann Liebert Publishers <https://www.liebertpub.com/>

A leading independent publisher known worldwide for its peer-reviewed journals, books, and trade publications

MediCity Nottingham www.biocity.co.uk/locations/medicity-nottingham/

Provide a stimulating and supportive business development environment for innovators in consumer healthcare, medical technology, diagnostics and beauty products

MEPC Milton Park www.miltonpark.co.uk

A premium business and science park located near Abingdon. Part of the MEPC group

Middle East Medical Portal www.middleeastmedicalportal.com

The premier medical portal between the West and the Middel East

Mills & Reeve www.mills-reeve.com

A commercial law firm offering corporate, commercial, property, litigation and private client services to a mix of regional, national and international businesses

North 51 www.north-51.com

Engages in building, managing, and motivating sales teams including contract sales teams, nurse adviser teams, NHS liaison teams and specialist hospital teams

Odgers Berndtson www.odgersberndtson.com/en-nl

Specialises in recruiting and assessing senior executives and board members in the private, public and not-for-profit sectors internationally

Osborne Clarke www.osborneclarke.com

Provide legal services to meet clients' advisory, litigation and transactional needs in an international business environment that is reshaping to meet new digital, economic, environmental and political challenges

Oxford Bioescalator www.bioescalator.ox.ac.uk

Provide flexible lab space near the centre of Oxford to early stage biomedical science companies

Oxford Science Park www.oxfordsp.com

Is designed for science, technology and business occupiers, maintains links with the University of Oxford and currently contains just over 70 companies

Oxford Seating Co www.oxfordseating.co.uk

Designs and manufactures seating and related furniture for companies in many different industries

Penningtons Manches Cooper www.penningtonslaw.com

Is a law firm providing legal services to ultra high net worth individuals and growing mid-market companies.

PharmaGuide www.pharmaguide.co.uk

Offer drug discovery courses to a range of clients from professionals with no scientific background, up to PhD level scientists

Phoenix IFD

www.linkedin.com/in/james-robson-943ab41/?originalSubdomain=uk

A life sciences and healthcare consulting business that focuses on innovative start ups in the pharmaceutical, healthcare and medtech sectors

PIA Life Science Insurance Brokers

www.piacommercial.com

Provide a range of specialist insurance products for individuals and businesses, including those in the life sciences sectors

PIR

www.pir-intl.com

A specialist recruitment company serving the international life sciences industry through executive search, interim management and talent management/mapping

Premier Choice Group

<https://pch.uk.com/>

Provides health insurance services to individuals and corporate clients

ProcEurope

www.proceurope.com/

Providing the power of a purchasing consortium to the life sciences sector in Europe through providing negotiable rates and specially selected suppliers

Release Life Sciences and Diagnostics

www.releaselifesciences.com

Help life science and diagnostics companies by providing commercial and marketing management services, interim management, training and development and career development and coaching

Richardsons Chartered Accountants

www.richardsons-group.co.uk

Provide accounting, audit and taxation advice (compliance and planning) to enterprises and individuals, along with payroll and financial services

Ridgefield Consulting

www.ridgefieldconsulting.co.uk

An independent firm of Chartered Accountants provides accounting, tax advice and planning to businesses and individuals

Scius Communications

www.sciuscommunications.com

Scius Communications is focused on providing strategic communications to life science companies at all stages of development

Sharp Clinical Services

www.sharpservices.com

Offers a complete range of packaging solutions, including design and serialisation, for blisters, bottles, specialty and injectables

SJB Technical Recruitment

www.sjbtechnical.co.uk

Specialises in recruiting engineers and scientists to start-ups and SMEs with particular focus on medical engineering, engineering design consultancies, entrepreneurial firms and new technology

SRG

www.srg.co.uk

Is UK supplier of scientific, clinical and engineering recruitment solutions to the pharmaceutical, biotechnology, medical devices, FMCG, renewable energy, chemical and food processing industries

Sue Rees Associates

www.suerees.co.uk

An accountancy executive search specialist supporting board level executives within the biotech, pharma, life sciences, start up and spin out companies

SynbiCITE

www.synbicite.com

The UK's national centre for the commercialisation of synthetic biology, providing a bridge between academia and industry to increase the development of new technologies in synthetic biology

TBAT Innovation

www.tbat.co.uk

An independent consultancy that provides services and advice on grant funding, R&D taxation, and project management

The IP Asset Partnership

www.ipasset.com/

A specialist practice of patent attorneys that provide specific advice or assistance on all IP related matters

Unit DX

www.unitdx.com

A Bristol-based scientific innovation centre, catering for start-ups, SMEs and industrial team providing lab space, equipment, analytical services, expert support and facilitates cooperation between companies

Utility Team

www.utilityteam.co.uk

One of the UK's leading utilities and energy consultants, providing a wide range of value added utility that saves time and money

VA Beach Bio

www.vabeachbio.com

A business organisation that aims to market the Virginia Beach area as a prime location for life sciences companies moving to the US

Venner Shipley

www.vennershipley.co.uk

Is a firm of European patent and trade mark attorneys, representing a broad range of clients including major domestic and international corporations, SMEs, universities and individual inventors

ViridisGroup

www.viridisgroup.com

Is an executive search firm specialising in the life science and healthcare sectors

Walder Limited

www.wallder.com

A UK-based executive search, interim management, and resourcing company that builds boards and senior management teams in the life sciences sector

Inventya Ltd

www.inventya.com

Inventya provide bespoke innovation support for SMEs, Universities, and Academic groups including bid writing and grant funding, R&D tax credit and Patent Box advice, finance for growth and collaborative R&D partnerships

Hayes Parson Insurance Brokers

www.hayesparsons.co.uk

Independent insurance brokers for the South West of England

Discovery Park Limited

www.discovery-park.co.uk

A science park based on the old Pfizer site at Sandwich and home to a growing number of life sciences companies

Pinsent Masons

<https://www.pinsentmasons.com>

Pinsent Masons provide legal services to diverse sectors including the life sciences

OEG Laboratories

www.oeglabs.co.uk

OEG Labs offers a full project-managed lab fit-out solution, from initial design through to custom manufacture and installation to customers in the UK

Fourtold Ltd

www.fourtold.eu

Experts in corporate, reputation and political communications

Dzaleta Consulting

<https://dzaletaconsulting.com/>

Provides executive and non-executive search services

Etheo Limited

www.etheolimited.com

Provide leadership training courses specifically tailored to the pharma and biotech sectors

Government Organisation**AMR Centre UK**

www.amrcentre.com

AMR Centre is a key part of the UK's response to the global threat from antimicrobial resistance to accelerate the development of new antimicrobial drugs and diagnostics

Embassy of Belgium

www.diplomatie.be

The London embassy of the Belgian Government and is active in the area of life sciences and collaboration between the UK and Belgium

Embassy of Switzerland, London - Office of Science, Technology and Higher Education

www.eda.admin.ch

The Office serves as an interface between the science and technology communities in Switzerland and the UK by providing information and facilitating contacts. The office works with government, universities and business to organise bilateral networking, matchmaking events and joint projects

Innovate UK

www.innovateuk.org

Work with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy and provides invaluable support to the life sciences through its grants programmes

Medicines Discovery Catapult

www.md.catapult.org.uk

Is a national facility for collaborative R&D projects and developing new approaches to the discovery and proof of utility of medicines, diagnostics and biomarkers

Public Health England

www.gov.uk/government/organisations/public-health-england

Their mission is to protect and improve the nation's health and to address inequalities through working with national and local government, the NHS, industry and the voluntary and community sector

West Midlands Growth Company

www.wmgrowth.com

A regional investment promotion and economic development agency, unlocking potential for the West Midlands and the UK with the primary purpose is to attract investment, jobs, visitors and business to the West Midlands

Netherlands Foreign Investment Agency

www.investinholland.com

The inward investment agency for The Netherlands

The HR Dept Ltd

www.hrdept.co.uk/newbury

Provide HR services to support companies with employment contracts, managing disciplinaries or other employment issues

OBN Purchasing



MAKING MEMBERS' MONEY WORK HARDER BY FACILITATING A GROUP – PURCHASING SOLUTION

Supporting the Life Sciences Industry

Your money working smarter

One of the major services that we offer Members is our Purchasing Consortium. Read on to find out how it works and what kind of savings your company could be making

How does it work?

- Average savings up to 50% against list price
- Big or small, office or laboratory – any type of business can save money
- Low cost of entry – all OBN full Members are eligible to take part
- UK's most comprehensive and cost-effective group-purchasing solution for life sciences companies
- 110 plus Member companies together saved more than £10 million in the last two years
- Managed by a full-time, in-house Procurement Manager
- Capital expenditure support

- Negotiation service
- Guidance and support on e-Procurement
- New suppliers regularly added
- OBN has a new online Purchasing Platform
- European Life Science companies can save money via our partner, ProcEurope

110 MEMBER COMPANIES TOGETHER SAVED MORE THAN £10 MILLION IN THE LAST TWO YEARS

Savings analysis

OBN has five levels of Membership fees depending on the size of your company.

See some example savings in the chart below.

Company Size	Spend without discount	Spend with discount	Savings	% Saved
Sole trader/Micro company (1-5)	£9,342	£3,134	£6,208	66.5%
Small company (6-20)	£131,673	£68,824	£67,849	47.7%
Medium company (21-50)	£172,977	£51,277	£121,750	70.4%
Large company (51-100)	£461,822	£327,388	£134,434	29.1%



For more information about Purchasing please contact the Head of Purchasing and Membership, Lee Pratley on Lee.pratley@obn.org.uk or call +44 (0)1235 420 876. Please contact leepratley@ProcEurope.com for more information about ProcEurope.



Celebrating Innovation & Achievement in Life Sciences



OBN AWARDS 2020

LONDON 26 NOVEMBER

Westbourne Suite,
Royal Lancaster Hotel
London W2

www.obn-awards.com
@OBN_UK
#OBNAwards

NEXT ISSUE

CONNECT issue 3 will be available
Autumn 2020

Please contact Rebecca Wilkes,
Communications and
Marketing Coordinator,
rebecca.wilkes@obn.org.uk,
if you would like :

- to contribute to the
next CONNECT
- place an advert
- provide feedback

We look forward to
hearing from you!



Contact details:

Main Office

OBN (UK) Ltd
5F Park Square, Milton Park, Abingdon,
Oxfordshire, OX14 4RR, UK

Tel: +44 (0) 1235 420 870

www.obn.org.uk



@OBN_UK



OBN (UK) Ltd